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CHAPTER I 
 
INTRODUCTION 
 
DNA Topology 
 One of the most striking features of DNA is the intertwining of the two 
complementary strands of the double helix (1). Discovery of this characteristic 
led to the immediate recognition that biological processes such as replication 
would be severely affected by the topological state of the genetic material (2).   
 DNA in all species ranging from bacteria to humans is globally underwound 
(i.e., negatively supercoiled) (3-6). This underwinding makes it easier to separate 
complementary DNA strands from one another and greatly facilitates initiation 
of replication and the assembly of replication forks. Once the fork begins to 
travel along the DNA template, however, the deleterious effects of topology 
manifest themselves (Figure 1). Since helicases separate, but do not unwind the 
two strands of the double helix, fork movement results in acute overwinding (i.e., 
positive supercoiling) of the DNA ahead of the replication machinery (Figure 1B) 
(3,5-7). This overwinding has two major consequences. First, it increases the 
difficulty of separating duplex DNA into individual strands. Therefore, 
accumulation of positive supercoils presents a formidable block to fork 
movement (5,7-11). Second, DNA overwinding ahead of the fork leads to a 
compensatory underwinding behind the replication machinery. If the replisome 
rotates around the helical axis of the DNA, this underwinding allows some of the 
torsional stress in the pre-replicated DNA to be translated to the newly replicated 
daughter molecules in the form of precatenanes (Figure 1C) (6,7,11). If these  
 2 
Figure 1. Model for topoisomerase function and topological stress associated 
with DNA replication [adapted from Wang (3)]. The replication machinery is 
represented by a rod moving through the double helix. DNA ends are anchored 
to hypothetical immobile structures existing in the nucleus. A, Upon initiation of 
DNA replication, the two strands of duplex DNA are separated and the 
replication fork is formed. B, Movement of the replication machinery through the 
immobilized DNA template strands induces acute overwinding (i.e., positive 
supercoiling) ahead of the fork. C, If the replisome rotates around the helical axis 
of the DNA, compensatory underwinding (i.e., negative supercoiling) behind the 
replication machinery allows some of the torsional stress in the pre-replicated 
DNA to be translated to the newly replicated daughter molecules in the form of 
precatenanes. If these precatenanes are not resolved, they ultimately lead to the 
formation of catenated duplex daughter chromosomes. Topoisomerase I is 
proposed to work ahead of the replication fork to remove positive DNA 
supercoils, while topoisomerase II is proposed to work primarily behind the fork 
to remove precatenanes.  
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precatenanes are not resolved, they ultimately lead to the formation of catenated 
duplex daughter chromosomes. 
 
DNA Topoisomerases 
 The topological state of DNA in the cell is modulated by enzymes known as 
topoisomerases (5,7,12-16). These ubiquitous enzymes regulate DNA over- and 
underwinding, and remove knots and tangles from the genetic material by 
creating transient breaks in the sugar-phosphate backbone of the double-helix 
(5,7,12-18). Topoisomerases maintain genomic integrity during this process by 
forming covalent attachments between their active site tyrosyl residues and the 
terminal DNA phosphates generated during the cleavage reaction (7,12,15,16). 
This covalent linkage is the hallmark characteristic of all DNA topoisomerases. 
The actions of these enzymes allow the progression of virtually all metabolic 
events in the cell. 
 
Topoisomerase I 
 There are two classes of topoisomerases that are distinguished by their 
catalytic mechanisms. Type I enzymes act by generating a transient single-
stranded break in the double helix, followed by either a single-stranded DNA 
passage event or controlled rotation about the break (14,19,20). As a result, type I 
topoisomerases are able to alleviate torsional stress (i.e., remove superhelical 
twists) in duplex DNA. These enzymes are further divided into two sub-classes. 
Type IA topoisomerases form a 5’-phosphotyrosyl linkage to the cleaved DNA 
strand, while type IB topoisomerases form a 3’-phosphotyrosyl linkage 
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(14,19,20). Human topoisomerase I belongs to the type IB subclass and will be 
further discussed in the following sections. 
 
Human Topoisomerase I Domain Structure 
 Human topoisomerase I consists of a single polypeptide of 765 amino acids 
(~91 kDa) and functions as a monomer (14,19,20). The enzyme is divided into 
four domains based on sequence homology between proteins of various species 
and sensitivity to proteolysis (Figure 2). The N-terminal domain (amino acids 1-
214) is highly variable and dispensable for activity in vitro. It contains nuclear 
localization sequences and sites for interaction with other proteins (20-22). The 
core domain of topoisomerase I (amino acids 215-635) is highly conserved and 
contains residues for enzyme catalysis, as well as DNA substrate recognition and 
binding (14,20,23,24). A dispensable linker domain (amino acids 636-712) is 
positioned between the core region and C-terminal domain of the enzyme. This 
linker domain is poorly conserved and interacts with the DNA substrate (20,25). 
Finally, the C-terminal domain of topoisomerase I (amino acids 713-765) is 
conserved and contains the active site tyrosine required for DNA cleavage and 
religation (14,20,23,24). 
 
Human Topoisomerase I Catalytic Cycle 
 Human topoisomerase I activity occurs independently of ATP or a divalent 
cation (though the presence of a divalent cation stimulates enzyme activity) 
(14,19). The catalytic cycle of topoisomerase I can be divided into five discrete 
steps (5,14,19): (1) site-specific, noncovalent binding of a DNA substrate; (2) 
generation of a single-stranded DNA break and covalent linkage to the 3’  
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Figure 2. Domain structure of human topoisomerase I. Domain organization of 
human topoisomerase I: N-terminal domain (yellow), core domain (red), linker 
(green), and C-terminal domain (blue). The N-terminal domain is variable and 
contains nuclear localization sequences and sites for protein interactions. The 
conserved core domain contains residues required for catalysis and substrate 
recognition. The linker region is poorly conserved and dispensable for catalysis. 
Finally, the conserved C-terminal domain contains the active site tyrosine (Y273) 
required for DNA cleavage/religation. 
 
NLS 
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terminus of the break, creating the “cleavage complex”; (3) controlled rotation of 
the double-helix around the single-stranded DNA break; (4) religation of the 
cleaved DNA strand, regenerating the active site tyrosine residue and re-
establishing noncovalent binding; (5) and enzyme dissociation or initiation of a 
new round of catalysis.  
 
Human Topoisomerase I Physiological Roles and Chemotherapeutic Target 
 Human topoisomerase I plays important roles in resolving torsional stress 
associated with the progression of DNA replication and transcription 
(5,13,19,20), and may have some involvement in maintaining genomic stability 
and chromosome condensation  (13,19,20). There also is evidence suggesting a 
role for topoisomerase I in transcription initiation independent of the catalytic 
activity of the enzyme (13,19). Though both yeast and mammalian cells lacking 
topoisomerase I are viable, the enzyme is required for embryogenesis in higher 
organisms, suggesting an additional essential role in early development (13,19). 
 In addition to the physiological role of topoisomerase I in cells, this enzyme 
is a target for an emerging class of anticancer agents derived from the 
compound, camptothecin (Figure 3). Camptothecin is a naturally occurring 
compound found in the bark of the Chinese tree Camptotheca acuminata (17,19,26-
28). Topotecan and CPT-11 (irinotecan) are derivatives of camptothecin and are 
U.S. FDA approved for ovarian and colon cancer (29). The most important aspect 
of these topoisomerase I-targeted drugs is that they act on a wide spectrum of 
cancers that currently have few, if any, other treatment options. Camptothecin 
was used in work described in chapter IV of this dissertation. 
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Camptothecin 
Topotecan 
CPT-11 (Irinotecan) 
Figure 3. Topoisomerase I-targeting agents. Camptothecin, topotecan, and cpt-
11 (irinotecan) are drugs that target topoisomerase I. Camptothecin is a naturally 
occurring compound found in the bark of the Chinese tree Camptotheca 
acuminata. Topotecan and CPT-11 are derivatives of camptothecin. The most 
important aspect of these drugs is that they act on a wide spectrum of cancers 
that currently have few, if any, treatment options. 
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Topoisomerase II 
 Type II topoisomerases act by generating a transient double-stranded DNA 
break, followed by a double-stranded DNA passage event (14-16,30). 
Consequently, these enzymes are able to remove superhelical twists from DNA 
and resolve knotted or tangled duplex molecules. Type II topoisomerases are 
required for recombination, chromosome segregation, and proper chromosome 
condensation and decondensation (5,7,12-16). 
 
Topoisomerase II Isoforms 
 Whereas lower eukaryotes such as yeast and Drosophila encode only a single 
type II topoisomerase (31,32), vertebrate species express two discrete forms of the 
enzyme, topoisomerase IIα and IIβ (14,18,33,34). These enzymes display a high 
degree of amino acid sequence identity (~70%) and similar enzymological 
characteristics. However, they differ in their protomer molecular masses (170 vs. 
180 kDa, respectively) and are encoded by separate genes (14,18,35). Either 
topoisomerase IIα or β can complement the loss of topoisomerase II in yeast (36-
38), but the two enzymes have distinct patterns of expression and physiological 
functions in vertebrate cells.  
 Topoisomerase IIα is upregulated dramatically during cell proliferation and 
is tightly associated with mitotic chromosomes (13,39-42). In contrast, expression 
of the β isoform is independent of proliferative status and the enzyme dissociates 
from chromosomes during mitosis (13,35,39,43). Thus, topoisomerase IIα is 
believed to be the isoform that functions in growth-dependent processes, such as 
DNA replication and chromosome segregation (7,13). While cells can survive the 
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absence of topoisomerase IIβ, this isoform cannot compensate for the loss of 
topoisomerase IIα (35,44,45).  
 
Topoisomerase II Domain Structure 
 The primary structures of topoisomerase IIα and β are very similar and can 
be divided into three domains based on sequence homology with the bacterial 
type II enzyme, DNA gyrase (5,14,15,18,35,46) (Figure 4).  
 N-terminal domain: The N-terminal domain (first ~670 amino acids) of 
topoisomerase II is homologous to the B-subunit of DNA gyrase (GyrB). This 
portion of the enzyme contains the site of ATP binding and hydrolysis (14,18,47). 
Crystal structures of this domain recently were solved for yeast topoisomerase II 
(48) and human topoisomerase IIα (49).  
 Central domain: The central domain (amino acids ~671-1200) of 
topoisomerase II is homologous to the A-subunit of DNA gyrase (GyrA) 
(14,18,50). This portion of the enzyme contains the active site tyrosine (amino 
acid 805 for topoisomerase IIα and 821 for topoisomerase IIβ) required for DNA 
cleavage and religation. A crystal structure for this domain in the absence of a 
DNA substrate was solved for yeast topoisomerase II (51). 
 C-terminal domain: The C-terminal domain (amino acids ~1201-1521 for 
topoisomerase IIα and ~1201-1621 for topoisomerase IIβ) is highly variable 
among species and between the two human isoforms. While it is dispensable for 
catalytic activity in vitro, this domain contains both nuclear localization 
sequences (52-58) and sites of phosphorylation (52,59-61). 
 While crystal structures have been solved for both the N-terminal and 
central domains of a eukaryotic topoisomerase II, a structure for the C-terminal  
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Figure 4. Domain structure of type II topoisomerases. The domain structures of 
E. coli DNA gyrase, human topoisomerase IIα and human topoisomerase IIβ are 
shown. Both human isoforms contain domains similar to the GyrB homology 
domain (blue), which is the ATPase region of the enzyme. They also encode 
regions homologous to the GyrA cleavage/religation domain (pink). This 
domain contains the active site tyrosine residue for topoisomerase II. The C-
terminal domain (yellow or green) of the type II enzyme is highly variable 
between different species of topoisomerase II and between the two human 
isoforms.  
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domain of the enzyme has yet to be solved. However, within the last year, 
several groups have provided structural information on the C-terminal domains 
of the two bacterial type II enzymes. These groups revealed that the C-terminal 
domains of DNA gyrase (GyrA) and topoisomerase IV (ParC) adopt a unique 
fold called a β-pinwheel (Figure 5, left panel) (62-64). The outer rim of this fold 
was observed to be positively charged (Figure 5, right panel) and is thought to 
both bind and bend DNA substrates.  
 Further evidence suggests that the C-terminal domains of DNA gyrase and 
topoisomerase IV have a profound effect on enzyme activity. Truncation of the 
C-terminal domains of both enzymes weakens their catalytic activity (64). In 
addition, the C-terminal domains of DNA gyrase and topoisomerase IV appear 
to be responsible for the preference of each enzyme for a specific DNA substrate 
(62-65). For example, deletion of the C-terminal domain of Escherichia coli 
topoisomerase IV abolishes the ability of the enzyme to preferentially relax 
positively supercoiled DNA substrates, though it does not abolish enzyme 
activity altogether (64).   
 While there currently are no structural data for the C-terminal domain of a 
eukaryotic type II enzyme, recent enzymological data suggests that the C-
terminal domain of human topoisomerase IIα also impacts enzyme activity. This 
idea will be discussed further in chapter V of this dissertation. 
 
Topoisomerase II Catalytic Cycle 
 Human topoisomerase IIα and β function as homodimers, and their catalytic 
activities are dependent on the presence of a divalent cation (such as 
magnesium) and ATP (15,18,46,66). Their catalytic cycles are virtually identical  
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Topo IV 
Gyrase 
Figure 5. C-terminal domain structure of bacterial type II topoisomerases. The 
C-terminal domain structures for the two bacterial type II topoisomerases, DNA 
gyrase (top) and topoisomerase IV (bottom) are shown (left panel). The overall 
structure is termed a β-pinwheel and is made up of several blades of β sheet 
DNA strands. Blades 1-6 for DNA gyrase are purple, blue, green, yellow, orange, 
and red, respectively (top, left panel). Blades 1-5 for topoisomerase IV are purple, 
blue, green, yellow, and orange, respectively (bottom, left panel). The electrostatic 
surface of the side (top, right panel) and top (bottom, right panel) views of the C-
terminal domain of topoisomerase IV also is shown. The curved, positively 
charged outer surface likely comprises the DNA binding surface. These images 
were adapted from Corbett et al. and Corbett et al. (62,64). 
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and can be divided into six discrete steps. One round of catalysis by 
topoisomerase II is depicted in Figure 6. 
 Step 1: Topoisomerase II preferentially interacts with DNA crossovers (67-
69). To initiate catalysis, the enzyme noncovalently binds two segments of DNA 
termed the G-segment (the double helix that is cleaved by the enzyme and is 
opened as a “gate”) and the T-segment (the double helix that is “transported” 
through the open DNA gate) (30). There is no cofactor requirement for this initial 
binding (70). 
 Step 2: In the presence of a divalent cation, a pre-strand passage 
cleavage/religation equilibrium is established (70-73). While magnesium is 
thought to be the physiologically relevant divalent cation for this process, others 
such as calcium can substitute in vitro (73,74). 
 The two monomers of topoisomerase II each cleave one strand in the G-
segment, resulting in a transient double-stranded break in the DNA. Sites of 
cleavage within the homodimer are four bases apart, generating a 4-base 5’ 
overhang on either side of the double-stranded break (71,72). In order to 
maintain genomic integrity, the active site tyrosyl residue of each monomer 
forms a covalent attachment to the new 5’ termini of the cleaved DNA strands 
(50,71,72,75). This transient intermediate is called the “cleavage complex”. While 
essential for maintaining the integrity of the genetic material, high concentrations 
of these complexes are potentially harmful for cells (15,16,76-78). 
 Unlike a traditional ligase, which requires base pairing to correctly position 
DNA ends for rejoining (79,80), topoisomerase II can religate cleaved DNA 
strands in the absence of base pairing interactions (81). Therefore, it is believed 
that topoisomerase II relies on covalent protein-DNA interactions to correctly  
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Figure 6. The catalytic cycle of topoisomerase II. The catalytic cycle of 
topoisomerase II is shown in six discrete steps: 1) Topoisomerase II-DNA 
binding; 2) Pre-strand passage DNA cleavage/religation equilibrium; 3) ATP 
binding and DNA strand passage; 4) Post-strand passage DNA 
cleavage/religation equilibrium; 5) ATP hydrolysis and gate opening; 6) DNA 
release and enzyme turnover.  
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position the 5’ termini of the cleaved strands for religation (81) and noncovalent 
interactions to position the 3’ termini (82). 
 Step 3: Each protein monomer binds a molecule of ATP, resulting in a 
conformational change and passage of the intact T-segment DNA through the 
cleaved G-segment (67,68,83,84). Hydrolysis of one ATP molecule appears to 
stimulate the passage event (85). Translocation of the T-segment DNA through 
the N-terminal gate of topoisomerase II and closure of this gate forms what is 
termed a “protein clamp” (68,86). This conformation topologically links the 
enzyme to the DNA, allowing it to diffuse along the double helix without 
dissociation. 
 Step 4: Following DNA strand passage, the enzyme religates the cleaved 
double helix and establishes a post-strand passage cleavage/religation 
equilibrium (68). 
 Step 5: Upon hydrolysis of a second molecule of ATP, topoisomerase II 
undergoes another conformational change that results in the opening of the C-
terminal gate (84,87).  The T-segment DNA strand is released through this gate 
(67,68,86,88). 
 Step 6: Finally, the enzyme returns to its original conformation and can 
either remain associated with the DNA substrate for a new round of catalysis, or 
it can dissociate and begin catalysis on a new substrate (67,68). 
 
Topoisomerase II-DNA Cleavage Complexes 
 Topoisomerase II-DNA cleavage complexes are transient in nature and their 
cellular concentration is tightly regulated (Figure 7). Cleavage complex 
formation is essential for topoisomerase II to perform is cellular functions  
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Figure 7. Effects of topoisomerase II-cleavage complexes in the cell. 
Topoisomerase II-DNA cleavage complexes are transient in nature, and their 
cellular concentration is tightly regulated. Cleavage complex formation is 
essential for topoisomerase II to perform is cellular functions. If the level of 
topoisomerase II-DNA cleavage complexes falls too low, cells are unable to 
undergo chromosome segregation, resulting in slow growth rates and ultimately 
cell death due to mitotic failure. Alternatively, if levels of cleavage complexes are 
too high, they can be converted to permanent strand breaks. The resulting strand 
breaks, as well as the inhibition of essential DNA processes, initiate multiple 
recombination/repair pathways. Accumulation of DNA breaks can lead to 
chromosome breakage and translocations. If the accumulation of breaks becomes 
overwhelming, they trigger cell death pathways. 
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(5,15,16). If the level of topoisomerase II-DNA cleavage complexes falls too low 
(i.e. enzyme activity is lowered), cells are unable to undergo chromosome 
segregation (7,12-16). This loss of enzyme activity results in slow growth rates 
and ultimately cell death due to mitotic failure.  
 While formation of the cleavage complex is essential to enzyme activity, it 
also is potentially deleterious to the cell. Transient, covalently linked 
topoisomerase II-DNA strand breaks are converted to permanent DNA strand 
breaks when nucleic acid tracking systems, such as replication or transcription 
complexes, attempt to traverse these topoisomerase-DNA roadblocks in the 
genetic material (Figure 8) (15,16,19,89,90). The resulting strand breaks, as well as 
the inhibition of essential DNA processes, initiate multiple recombination/repair 
pathways (15,16,76-78). Accumulation of DNA breaks can lead to chromosome 
breakage, DNA translocations, and cancer (Figure 8) (66,76,78). If the 
accumulation of breaks becomes overwhelming, they trigger cell death pathways 
(77). There are several different classes of topoisomerase II-targeting compounds 
that either stimulate or inhibit cleavage complex formation in cells. 
 
Topoisomerase II-Targeting Agents 
 Beyond the critical physiological functions of type II topoisomerases, these 
enzymes are targets for some of the most important anticancer drugs currently 
used for treating human malignancies (15-19,91-94). One of these drugs, 
etoposide, has been used in the clinic since the 1960’s (91,92,94). It is prescribed 
as treatment for a wide spectrum of leukemias, lymphomas, and solid tumors. 
The relative contributions of topoisomerase IIα and β to therapeutic outcomes are 
not clear at the present time. Because topoisomerase IIα is upregulated in many  
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Figure 8. Conversion of transient topoisomerase II cleavage complexes to 
permanent double stranded DNA breaks. Transient, covalently linked 
topoisomerase II-DNA strand breaks are converted to permanent DNA strand 
breaks when DNA tracking systems, such as replication or transcription 
complexes, attempt to traverse these topoisomerase-DNA roadblocks in the 
genetic material. The resulting strand breaks initiate multiple 
recombination/repair pathways Accumulation of DNA breaks can lead to 
chromosome breakage, DNA translocations and cancer, and ultimately trigger 
cell death pathways. 
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cancer cells and is the isoform believed to be involved in DNA replication, it has 
been assumed to be an important drug target. In addition, drug interactions with 
topoisomerase IIβ in differentiated tissues, such as heart, are believed to 
contribute to the dose-limiting toxicity of some agents (95-98). 
 
Topoisomerase II Poisons 
 Topoisomerase II-targeting agents represent a structurally diverse group of 
natural and synthetic compounds. Some of these compounds are depicted in 
Figure 9. Etoposide is a non-intercalative drug that was among the earliest 
anticancer agents identified as targeting topoisomerase II (15,16,91,92,94,99). 
TOP-53 is a non-intercalative drug that is a more potent derivative of etoposide 
(100,101). Genistein and CP-115,953 are non-intercalative compounds that share a 
similar core ring structure. Genistein is a naturally occurring bioflavanoid that is 
believed to possess chemopreventative properties (102-104). CP-115,953 belongs 
to the quinolone family (15,105-108), a drug class that includes a number of 
widely used antibacterials that target prokaryotic type II topoisomerases. TAS-
103 displays strong interactions with DNA and is both an outside binder and an 
intercalating agent (109-111). Finally, amsacrine is an intercalative compound 
that is in clinical use (15,112,113). Each of these topoisomerase II-targeting drugs 
was utilized in the work described in chapter IV of this dissertation. 
 Although topoisomerase-targeted anticancer drugs come from several 
different structural classes, they all act by increasing levels of covalent 
topoisomerase-cleaved DNA complexes (i.e., cleavage complexes) that are 
requisite intermediates in the catalytic cycles of these enzymes (15,16,19,89,90). 
When DNA tracking systems, such as replication forks, collide with these  
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Figure 9. Topoisomerase II-targeting agents. The structures of four 
topoisomerase II poisons, etoposide, CP-115,953, genistein and amsacrine, are 
shown (top). These drugs function by increasing levels of topoisomerase II-
mediated DNA cleavage complexes. The structures of two topoisomerase II 
catalytic inhibitors also are shown (bottom). These drugs function by blocking 
specific steps in the catalytic cycle of topoisomerase II.  
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complexes, transient enzyme-associated DNA breaks are converted to permanent 
breaks in the genome (15,16,19,34,90,114). As a result, anticancer agents convert 
topoisomerases from essential enzymes to potent cellular toxins, and are thus 
called topoisomerase II “poisons.” 
 Topoisomerase II poisons increase levels of enzyme-DNA cleavage 
complexes by two non-mutually exclusive mechanisms. Some drugs, such as 
etoposide, genistein, TOP-53, amsacrine and TAS-103, act by inhibiting the 
ability of topoisomerase II to ligate the cleaved substrate (15,16,94,115,116). These 
drugs not only increase the level of cleavage complexes, but also increase the 
lifetime of these complexes. Other drugs, such as CP-115,953, have little effect on 
the rate of enzyme-mediated ligation and are believed to act primarily by 
enhancing the forward rate of cleavage complex formation (116-118). The exact 
mechanism by which this second group of drugs increases levels of DNA 
cleavage is unknown. They may specifically act to enhance the forward rate of 
DNA scission. Alternatively, they may have some effect on the DNA 
binding/dissociation equilibrium, as the level of topoisomerase II-mediated 
DNA cleavage is proportional to the amount of enzyme bound (118,119). 
 Drugs that target topoisomerases are believed to work at the enzyme-nucleic 
acid interface (15,16,119-124). However, intercalative agents, such as amsacrine 
and TAS-103, have two additional effects on DNA that could impact levels of 
topoisomerase-mediated scission in a geometry-specific manner. First, since 
these compounds locally underwind DNA, they induce compensatory 
unconstrained positive superhelical twists in distal regions of covalently closed 
circular molecules (125,126). Thus, as the concentration of an intercalating agent 
increases, a plasmid that is topologically negatively supercoiled would appear to 
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contain positive superhelical twists. Second, the accumulation of drugs in the 
double helix has the potential to inhibit enzyme binding or activity. Because the 
generation of positive superhelical twists by DNA intercalation induces torsional 
stress in the double helix, the ability of covalently closed molecules to absorb 
these compounds is limited. Since overwound plasmids are under positive 
torsional stress even in the absence of drugs, they cannot bind as many 
intercalative molecules as underwound DNA. These two characteristics of 
intercalative compounds have a profound effect on the ability of human type II 
topoisomerases to cleave negatively and positively supercoiled DNA substrates 
and will be discussed further in chapter IV of this dissertation. 
 
Topoisomerase II Catalytic Inhibitors 
 While the only drugs currently being used in the clinic are topoisomerase II 
poisons, there is another class of topoisomerase II-targeting agents termed 
catalytic inhibitors. These drugs do not increase the level of enzyme-mediated 
DNA cleavage complexes. Instead, they block specific steps in the catalytic cycle 
of topoisomerase II (127-129). For example, agents such as novobiocin inhibit 
ATP binding (130,131). Merbarone, on the other hand, has been shown to block 
DNA cleavage mediated by topoisomerase II (128,132,133). These two catalytic 
inhibitors are depicted in Figure 9. 
 Whereas topoisomerase II poisons kill cells by fragmenting the genome, 
catalytic inhibitors kill cells by depriving them of the essential activity of 
topoisomerase II. Cells treated with catalytic inhibitors result in elongated and 
entangled chromosomes and ultimately die from mitotic failure (134-136). While 
topoisomerase II poisons are used as chemotherapeutic agents, catalytic 
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inhibitors have been used as modulators to increase the activity of other drugs 
(15,129,134). Additionally, some catalytic inhibitors have displayed potential 
anticancer activity in model organisms and currently are being tested in clinical 
trials (128,129,134,137). 
 
Topoisomerase II and Cancer 
  
Topoisomerase II as a Cellular Target for Anticancer Agents 
 Several pieces of evidence have been presented throughout the years 
indicating that certain anticancer drugs specifically target DNA topoisomerases. 
The initial suggestion that topoisomerases could be a target for such drugs came 
from the laboratory of Dr. Kurt Kohn in the late 1970s. This laboratory found that 
protein-associated DNA breaks were formed in cells treated with intercalative 
compounds (138,139). A few years later, Dr. Leroy Liu and co-workers published 
data demonstrating that certain anticancer drugs specifically stimulate 
topoisomerase II-mediated DNA cleavage both in vitro and in vivo (112,140-143). 
 In addition to this early data, Dr. John Nitiss and co-workers have developed 
yeast models for studying cellular resistance or hypersensitivity to 
topoisomerase II-targeted drugs (144-149). Cellular sensitivity to topoisomerase 
II-targeted drugs reflects the physiological level or activity of the enzyme 
(144,145,147,150,151). Cells that contain increased amounts of topoisomerase II 
display a hypersensitivity to drugs that target this enzyme. This is due to a 
higher level of topoisomerase II-mediated DNA strand breaks that cause cell 
death. In contrast, cells that contain decreased amounts of the enzyme display 
resistance to topoisomerase II-targeted drugs. This is due to a lower level of 
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topoisomerase II-mediated DNA cleavage, which is less toxic to cells. Finally, 
mutant type II topoisomerases that are hypersensitive or resistant to an 
anticancer drug in vitro have displayed the same hypersensitivity or resistance to 
the drug in cells (145,149,152-157).  
 
Initiation of Cancer by Topoisomerase II 
 While topoisomerases are important targets for treating human cancers, 
there is some evidence suggesting that these enzymes also may be responsible 
for initiating cancers. More specifically, topoisomerase II-mediated DNA 
cleavage is believed to induce chromosomal translocations that lead to the 
development of specific types of leukemia (78,158-164). A small percentage of 
patients treated with etoposide-based chemotherapeutic regimens go on to 
develop specific treatment-related leukemias (163), the majority of which contain 
translocations at a breakpoint region in the MLL (mixed lineage leukemia) gene 
at chromosome band 11q23 (78,158,159,165-170). In correlation with these clinical 
data, etoposide was found to induce topoisomerase II-mediated DNA cleavage 
proximal to the chromosomal breakpoint region (171).  
 In addition to treatment-related leukemias, topoisomerase II is thought to be 
involved in the initiation of acute myeloid leukemias (AMLs) in infants (170,172-
174). These AMLs also are the result of chromosomal translocations involving the 
MLL gene, although these translocations are observed in utero (174-176). 
Epidemiological studies have indicated that maternal consumption of foods 
during pregnancy that are high in naturally occurring topoisomerase II poisons 
increases the risk of developing infant AMLs ~10-fold (177,178). These findings 
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suggest that topoisomerase II-mediated DNA breaks may be initiating these 
translocations.  
 AMLs, along with non-lymphocytic leukemias, also have been linked to 
exposure to chemicals, such as benzene (179-186). Benzene is one of the top 
twenty production chemicals in the United States (187) and is both clastogenic 
and carcinogenic in humans (179-183,188). The mechanism by which benzene 
induces leukemias has not been fully elucidated, but it is thought to be through 
one of benzene’s metabolites, 1,4-benzoquinione (189,190).  Exposure of 
mammalian cells to 1,4-benzoquinone generates DNA mutations, insertions, 
deletions, and strand breaks (182,189,191-193). In addition, 1,4-benzoquinone 
was recently demonstrated to be a topoisomerase II poison (194). 
 The ability of topoisomerase II to cause rather than cure cancer is most likely 
related to the level of enzyme activity in a particular cell. If the concentration of 
topoisomerase II-mediated DNA cleavage in a cell is high, then recombination 
and repair pathways will be overwhelmed and cells will initiate apoptosis (77). 
However, if the concentration of topoisomerase II-mediated DNA cleavage is too 
low to initiate cell death, chromosomal breaks and translocations can result from 
normal cell survival pathways (66,76,78). These translocations can then 
ultimately lead to cancerous cell growth. Therefore, while topoisomerase II is an 
important target for cancer treatment, there also are potentially deleterious 
effects of targeting these enzymes. 
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Scope of the Dissertation 
 Topoisomerases play critical roles during DNA replication in eukaryotic 
cells (5,7,12-16). Since human topoisomerase I can relax positive or negative 
superhelical twists (14,19,195), it has been assumed that this enzyme acts ahead 
of replication forks to alleviate torsional stress. Conversely, because type II 
topoisomerases can untangle duplex DNA molecules (12,14-16,30), these 
enzymes are believed to act exclusively behind forks to resolve precatenanes or 
later in replication to unlink catenated daughter chromosomes. In marked 
contrast to this proposed segregation of function, models for anticancer drug 
action always place topoisomerase II ahead of approaching replication forks 
(15,16,90,196-198). This discrepancy raises the question of whether eukaryotic 
type II topoisomerases have normal physiological functions ahead of the DNA 
replication machinery. 
  If type II topoisomerases play a role ahead of replication forks in 
vertebrate species, then positively supercoiled DNA should be the preferred 
substrate for topoisomerase IIα, the isoform that is involved in replicative 
processes. Therefore, the goals of this dissertation are to 1) characterize the 
activity of human topoisomerase IIα and β on positively supercoiled DNA; 2) 
examine the effects of DNA supercoil geometry on topoisomerase-mediated 
DNA cleavage and enzyme response to anticancer drugs; and 3) explore the 
ability of topoisomerase IIα to recognize DNA supercoil geometry and determine 
what elements in the enzyme modulate substrate recognition. 
 Chapter I of this dissertation reviews both type I and type II topoisomerases, 
as well as the role of each enzyme in treating and/or initiating human cancers. 
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Chapter II describes the materials and methods utilized in the studies presented 
in Chapters III-V.  
 Chapter III of this dissertation characterizes the activity of human 
topoisomerase IIα and β on positively supercoiled DNA as compared to 
negatively supercoiled DNA. This work demonstrated that topoisomerase IIα, 
but not topoisomerase IIβ, preferentially relaxes positively supercoiled DNA 
over negatively supercoiled substrates. This preferential relaxation was not due 
to a greater binding affinity for positive supercoils or faster rates of religation 
with this substrate, and is most likely the result of faster DNA strand passage. In 
addition, topoisomerase IIα maintained lower levels of DNA cleavage 
intermediates with positively supercoiled plasmids, suggesting that the enzyme 
has the potential to relieve torsional stress ahead of approaching DNA tracking 
systems in an efficient and safe manner. The results of this study have been 
published (199). 
 Chapter IV of this dissertation examines the effects of positively supercoiled 
DNA on topoisomerase-mediated DNA cleavage, as well as the response to 
specific anticancer agents. This study includes human topoisomerase IIα and β, 
as well as human topoisomerase I. The human type II enzymes displayed lower 
levels of DNA cleavage in both the absence and presence of non-intercalative 
drugs. This was due primarily to lower baseline levels of cleavage, rather than 
decreased stimulation of scission by the drugs. Both topoisomerase IIα and β 
displayed higher relative cleavage enhancement with positively supercoiled 
substrates in the presence of intercalative drugs. This appeared to be the result of 
negative effects of high concentrations of intercalative compounds on negatively 
supercoiled DNA. Finally, topoisomerase I maintained higher levels of DNA 
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cleavage with a positively supercoiled substrate in the absence and presence of 
drug, indicating that this human enzyme may be an intrinsically more lethal 
target for anticancer drugs than either topoisomerase IIα or β. The results of this 
study have been published (200). 
 Chapter V of this dissertation explores the ability of topoisomerase II to 
recognize DNA supercoil geometry. While human topoisomerase IIα, but not 
topoisomerase IIβ, discerns supercoil geometry during DNA relaxation, both 
human isoforms discern the handedness of supercoils during DNA cleavage. 
These data suggest that type II topoisomerases must utilize distinct mechanisms 
to distinguish DNA geometry during these two processes. Several different 
enzymes were utilized to explore this hypothesis. 
 First, two chlorella virus type II topoisomerases (each naturally truncated at 
their C-terminal end) (201-204) were examined. Neither of these viral enzymes 
distinguished between negatively and positively supercoiled DNA during 
relaxation, but they each discerned DNA geometry during cleavage. Second, a 
truncation mutant of human topoisomerase IIα was created (205) and examined. 
This mutant enzyme also did not distinguish between negatively and positively 
supercoiled DNA during relaxation, but it discerned DNA geometry during 
cleavage. Finally, two mutants of topoisomerase IIα and β, in which the C-
terminal domains were switched, were created and examined. The ability of 
topoisomerase IIα to preferentially relax positively supercoiled DNA was shown 
to be modulated by its C-terminal domain.  
 Taken together, these results suggest a bimodal recognition of DNA 
supercoil geometry by topoisomerase II, in which the enzyme uses elements in 
the C-terminal domain to sense the handedness of supercoils during DNA 
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relaxation and elements in the conserved N-terminal or central domains to 
recognize supercoil geometry during DNA cleavage. Finally, concluding remarks 
for this dissertation are found in Chapter VI.   
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CHAPTER II 
 
METHODS 
 
Materials 
 Archaeoglobus fulgidus reverse gyrase was expressed in E. coli C41(DE3) and 
purified according to Rodriguez (206). Human topoisomerase IIα, topoisomerase 
IIβ, hTop2αΔ1175, hTop2αCTDβ, hTop2βCTDα, and yeast topoisomerase II were 
expressed in Saccharomyces cerevisiae (50) and purified as described previously 
(157,207). Drosophila melanogaster topoisomerase II was purified from embryonic 
Kc cells as described by Shelton et al. (208). Human topoisomerase I was a gift 
from Dr. Mary Ann Bjornsti (St. Jude Children’s Research Hospital). PBCV-1 
topoisomerase II and CVM-1 topoisomerase II were expressed in S. cerevisiae and 
purified by a modification (204) of the procedure of Lavrukhin et al. (201). 
Negatively supercoiled pBR322 DNA was prepared from E. coli using a Plasmid 
Mega Kit (Qiagen) as described by the manufacturer. Restriction enzymes, 
phosphatase, and T4 polynucleotide kinase were from New England Biolabs. [γ-
32P]ATP and genistein were obtained from ICN, etoposide and camptothecin 
were from Sigma, TOP-53 and TAS-103 were gifts from Taiho Pharmaceuticals, 
amsacrine was a gift from Bristol-Myers Squibb, and CP-115,953 was a gift from 
Pfizer Global Research. Etoposide, camptothecin, genistein, TOP-53, amsacrine, 
and CP-115,953 were stored at 4 oC as 10 or 20 mM stock solutions in 100% 
DMSO. TAS-103 was stored at 4 oC as a 10 mM stock solution in water. All other 
chemicals were analytical reagent grade. 
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Procedures 
 
Preparation of Positively Supercoiled DNA 
 Positively supercoiled plasmid DNA was prepared by treating negatively 
supercoiled molecules with reverse gyrase (206). Reaction mixtures contained 35 
nM negatively supercoiled pBR322 DNA and 420 nM reverse gyrase in a total of 
500 µL of 50 mM Tris-HCl (pH 8.0), 10 mM NaCl, 10 mM MgCl2, and 1 mM ATP. 
Reactions were incubated at 95 oC for 5 min, halted by the addition of 13 µL of 
375 mM EDTA, and cooled on ice. Proteinase K was added (10 µL of 4 mg/mL) 
and reactions were incubated at 45 °C for 30 min to digest the enzyme. Samples 
were extracted with phenol:chloroform:isoamyl alcohol (25:24:1) and positively 
supercoiled DNA was precipitated with cold ethanol. Plasmids were 
resuspended in 100 µL 5 mM Tris-HCl (pH 7.4) containing 500 µM EDTA. To 
make certain that differences between negatively and positively supercoiled 
substrates were not influenced by the temperature or other conditions used in 
the preparation protocol, negatively supercoiled plasmids were treated in a 
parallel fashion, except that reverse gyrase was omitted from reaction mixtures. 
 The average number of superhelical twists present in DNA substrates and 
the resulting σ values were determined by electrophoretic band counting relative 
to fully relaxed molecules. For negatively supercoiled substrates, time courses for 
the relaxation of pBR322 by topoisomerase I were resolved by electrophoresis in 
1% agarose gels in TBE [100 mM Tris-borate (pH 8.3), 2 mM EDTA] containing 1–
2 µg/mL chloroquine (Sigma) as running buffer. Optimal resolution was 
observed in 1 µg/mL chloroquine. For positively supercoiled substrates, time 
courses for the generation of positive superhelical twists by reverse gyrase were 
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resolved by electrophoresis as above in TBE containing 5–15 µg/mL netropsin B 
(Boehringer Mannheim). Optimal resolution was observed in 7.5 µg/mL 
netropsin B. Positively supercoiled bands also were counted in time courses of 
relaxation of positively supercoiled plasmid by topoisomerase I. Calculated σ 
values were consistent with those obtained from the reverse gyrase time courses.  
 
DNA Relaxation 
 DNA relaxation assays were based on the procedure of Fortune and 
Osheroff (133) or Dickey et al. (204). Unless stated otherwise, reaction mixtures 
contained 1 nM human topoisomerase IIα, topoisomerase IIβ, PBCV-1 
topoisomerase II or CVM-1 topoisomerase II, 0.2 nM yeast topoisomerase II, 2 
nM D. melanogaster topoisomerase II, 4 nM hTop2αΔ1175, 2 nM hTop2αCTDβ or 
hTop2βCTDα, 5 nM negatively or positively supercoiled pBR322 DNA, and 1 
mM ATP in a total of 20 µL of relaxation buffer [topoisomerase II α, 
topoisomerase IIβ, hTop2αΔ1175, hTop2αCTDβ, and hTop2βCTDα: 10 mM Tris-
HCl (pH 7.9), 0.1 mM EDTA, 175 mM KCl, 5 mM MgCl2, and 2.5% glycerol (v/v); 
yeast topoisomerase II: 10 mM Tris-HCl (pH 7.9), 0.1 mM EDTA, 100 mM NaCl, 5 
mM MgCl2, and 2.5% glycerol (v/v); D. melanogaster topoisomerase II: 10 mM 
Tris-HCl (pH 7.9), 0.1 mM EDTA, 50 mM KCl, 50 mM NaCl, 5 mM MgCl2, and 
2.5% glycerol (v/v); PBCV-1 or CVM-1 topoisomerase II: 10 mM Tris-HCl (pH 
8.5), 62.5 mM NaCl, 62.5 mM KCl, 0.1 mM EDTA, 2.5 mM MgCl2, and 2.5% 
glycerol (v/v)]. Samples were incubated at optimal temperatures, 37 °C (human), 
28 °C  (yeast), 30 °C (D. melanogaster and CVM-1) or 25 oC (PBCV-1), and DNA 
relaxation was stopped by the addition of 3 µL of 0.77% SDS, 77 mM EDTA (pH 
8.0). Samples were mixed with 2 µL of agarose gel loading buffer [60% sucrose in 
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10 mM Tris-HCl (pH 7.9)], heated at 45 °C for 2 min, and subjected to 
electrophoresis in a 1% agarose gel in 100 mM Tris-borate (pH 8.3), 2 mM EDTA. 
 Alternatively, DNA relaxation samples from assays using human 
topoisomerase IIα also were analyzed by two-dimensional gel electrophoresis. 
The first dimension was run for 2 h as described in the preceding paragraph. The 
gel was soaked for 2 h with gentle shaking in 200 ml of TBE containing 4.5 
µg/mL chloroquine and run in the orthogonal dimension (90º clockwise) for 2 h 
in fresh TBE containing 4.5 µg/mL chloroquine.  
        All gels were stained with 1 µg/mL ethidium bromide, and DNA bands 
were visualized with ultraviolet light and quantified using an Alpha Innotech 
digital imaging system. 
 
DNA Binding 
The ability of human topoisomerase IIα, PBCV-1 topoisomerase II, CVM-1 
topoisomerase II, and hTop2αΔ1175 to bind negatively and positively 
supercoiled DNA was assessed using a competitive nitrocellulose filter-binding 
assay. Binding mixtures contained 400 nM enzyme, 5 nM linear pBR322 DNA 
that was cleaved with Hind III and terminally labeled with [32P]phosphate, and 
0–20 nM negatively or positively supercoiled DNA in a total of 20 µL of binding 
buffer [topoisomerase IIα and hTop2αΔ1175: 10 mM Tris-HCl (pH 7.9), 100 or 175 
mM KCl, 0.1 mM EDTA, and 2.5% glycerol (v/v); or PBCV-1 and CVM-1 
topoisomerase II: 10 mM Tris-HCl (pH 8.5), 62.5 mM NaCl, 62.5 mM KCl, 0.1 mM 
EDTA, and 2.5% glycerol (v/v)]. Samples were incubated at optimal 
temperatures, 37 °C (human), 25 oC (PBCV-1) or 30 °C (CVM-1) for 6 min.  Under 
the conditions of the assay, a DNA binding equilibrium was established in less 
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than 1 min. Nitrocellulose membranes (0.45 µm HA, Millipore) were prepared by 
incubation in binding buffer for 10 min. Samples were applied to the membranes 
and filtered in vacuo. Membranes were washed 3 times with 1 mL of binding 
buffer, dried, and submerged in 8 mL of scintillation fluid (Econo-Safe, Research 
Products International). Radioactivity remaining on the membranes was 
quantified using a Beckman LS 5000 TD Scintillation Counter. The percent linear 
DNA bound to each enzyme was determined based on the ratio of radioactivity 
on the membranes vs. that of the input DNA.  
 It should be noted that DNA binding experiments were performed in the 
absence of ATP and Mg2+. This was done to prevent the formation of 
concatenated DNA multimers, which are too large to pass through the filter, or 
the generation of covalent enzyme-DNA cleavage complexes during the course 
of the assay. 
 
ATP Hydrolysis 
 ATPase assays were performed as described by Osheroff et al. (67).  Reaction 
mixtures contained 1 nM human topoisomerase IIα, 55 nM negatively or 
positively supercoiled pBR322 DNA, and 1 mM [γ-32P]ATP in a total of 40 µL of 
relaxation buffer.  Mixtures were incubated at 37 °C, and 2 µL samples were 
removed at time intervals up to 12 min and spotted on polyethyleneimine-
impregnated thin layer cellulose chromatography plates (EMD Chemicals). 
Plates were developed by chromatography in freshly made 400 mM NH4HCO3 
and analyzed using a Bio-Rad Molecular Imager FX. ATP hydrolysis was 
monitored by the release of free phosphate. 
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Plasmid DNA Cleavage 
 DNA cleavage reactions were carried out using the procedure of Fortune 
and Osheroff (133) or Dickey et al. (204). Reaction mixtures contained 0-800 nM 
topoisomerase IIα or hTop2αΔ1175, 0-1000 nM topoisomerase IIβ, 0-40 nM 
PBCV1 or CVM1, 10 nM negatively or positively supercoiled pBR322 DNA, and 
5 mM MgCl2 or CaCl2 in a total of 20 µL of cleavage buffer [topoisomerase IIα, 
topoisomerase IIβ, or hTop2αΔ1175: 10 mM Tris-HCl (pH 7.9), 100 mM KCl, 0.1 
mM EDTA, and 2.5% glycerol (v/v); PBCV-1 topoisomerase II: 10 mM Tris-HCl 
(pH 8.5), 62.5 mM NaCl, 62.5 mM KCl, 0.1 mM EDTA, 2.5 mM MgCl2, and 2.5% 
glycerol (v/v); or CVM-1 topoisomerase II: 10 mM Tris-HCl (pH 8.5), 120 mM 
KCl, 0.1 mM EDTA, 15 mM MgCl2, and 2.5% glycerol (v/v)]. Assays were carried 
out in the absence of compound or in the presence of 0-100 µM etoposide, 50 µM 
genistein or TAS-103, 25 µM TOP-53, 5 µM CP-115,953, 0–500 µM amsacrine, or 
0–25 µM ethidium bromide. Topoisomerase I DNA cleavage assays contained 11 
nM human topoisomerase I and 10 nM negatively or positively supercoiled 
pBR322 DNA in a total of 20 µL of 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 50 
mM KCl, 0.1 mM EDTA, 0.5 mM DTT, 30 µg/ml BSA. Mixtures were incubated 
at optimal temperatures, 37 °C (human), 25 oC (PBCV-1) or 30 °C (CVM-1) for 6 
min and enzyme-DNA cleavage complexes were trapped by the addition of 2 µL 
of 5% SDS (human) or 1% SDS (PBCV-1 and CVM-1), followed by 1 µL of 375 
mM EDTA, pH 8.0 (human) or 2 µL 115 mM EDTA, pH 8.0 (PBCV-1 and CVM-
1). Proteinase K (2 µl of 0.8 mg/mL) was added and samples were incubated at 
45 °C for 30 min to digest the type II enzymes.  Samples were mixed with 2 µL of 
agarose gel loading buffer, heated at 45 °C for 2 min, and subjected to 
electrophoresis in 1% agarose gels in 40 mM Tris-acetate (pH 8.3), 2 mM EDTA 
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containing 0.5 µg/mL ethidium bromide. DNA bands were visualized and 
quantified as described above and cleavage was monitored by the conversion of 
supercoiled plasmid DNA to linear molecules.  
 DNA cleavage reactions were performed in the absence of ATP so that the 
topological state of the DNA did not change during the course of the reaction. It 
should be noted that the nucleotide cofactor does not influence the mechanism of 
topoisomerase II-mediated DNA scission (15). 
 
Site-specific DNA Cleavage 
 DNA sites cleaved by human topoisomerase IIα, PBCV-1 topoisomerase II 
and CVM-1 topoisomerase II in negatively and positively supercoiled DNA were 
mapped using a modification of the procedure of O’Reilly and Kreuzer (74,209). 
DNA cleavage mixtures contained 2.2 µM topoisomerase IIα, 120 nM PBCV-1 or 
CVM-1 topoisomerase II, 10 nM negatively or positively supercoiled pBR322 
DNA, and MgCl2 or CaCl2 (human: 1 mM, PBCV-1: 2.5 mM, CVM-1: 15 mM) in a 
total of 160 µL of cleavage buffer. In some cases, reaction mixtures included 100 
µM etoposide. Samples were incubated at optimal temperatures, 37 °C (human), 
25 oC (PBCV-1) or 30 °C (CVM-1) for 6 min and enzyme-DNA cleavage 
complexes were trapped by the addition of 16 µL of 1% SDS followed by 8 µL of 
375 mM EDTA, pH 8.0 (human) or 16 µL of 115 mM EDTA (PBCV-1 and CVM-
1). Proteinase K (16 µL of 0.8 mg/mL) was added and mixtures were incubated at 
45 °C for 30 min to digest the type II enzyme. DNA products were purified by 
passage through Qiaquick Spin Columns (Qiagen) as described by the 
manufacturer. DNA cleavage products were linearized by treatment with 
HindIII. Terminal 5’-phosphates were removed by treatment with calf intestinal 
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alkaline phosphatase and replaced with [32P]phosphate using T4 polynucleotide 
kinase and [γ-32P]ATP. Samples were treated with EcoRI and the singly-end 
labeled DNA products were purified by passage through a CHROMA SPIN+TE-
10 column (Clontech). Loading buffer (40% formamide, 8.4 mM EDTA, 0.02% 
bromophenol blue, and 0.02% xylene cyanole FF) was added and samples were 
subjected to electrophoresis in 6% sequencing gels.  Gels were fixed in 10% 
methanol/10% acetic acid and dried in vacuo.  DNA cleavage products were 
visualized with a BioRad Molecular Imager FX. 
  The effects of ethidium bromide (0–10 µM) on the cleavage of linear DNA 
by topoisomerase IIα was monitored using the above protocol with the exception 
that a singly-end labeled linear pBR322 fragment (74,209) was used as the initial 
substrate. DNA cleavage was monitored by the loss of full-length linear 
molecules. 
 
DNA Religation 
  DNA religation assays for different type II enzymes were carried out by one 
of two procedures. The first is a modification of the procedure of Kingma et al. 
(210) and was used to measure the religation abilities of topoisomerase IIα, 
PBCV-1 topoisomerase II and hTop2αΔ1175. DNA cleavage/ligation equilibria 
were established in topoisomerase II cleavage buffer as described above except 
that MgCl2 in the reaction buffer was replaced by an equivalent concentration of 
CaCl2. Topoisomerase II-DNA cleavage complexes were trapped by the addition 
of EDTA (pH 8.0) to a 6 mM (human) or 10 mM (PBCV-1) final concentration. 
NaCl was added to a 500 mM (human) or 250 mM (PBCV-1) final concentration 
in order to prevent re-cleavage of the DNA substrate. Religation was initiated by 
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the addition of MgCl2 at a 0.25 mM (human) or 1 mM (PBCV-1) final 
concentration and terminated at times up to 60 s by the addition of 2 µL of 5% 
SDS (human) or 1 % SDS (PBCV-1). 
 The second method for DNA religation was carried out according to Dickey 
et al. (204) and was used to measure the religation activity of human 
topoisomerase IIα and CVM-1 topoisomerase II. DNA cleavage/ligation 
equilibria were established in topoisomerase II cleavage buffer as described 
above. Religation was initiated by shifting samples from 37 oC (human) or 30 oC 
(CVM-1) to 0 oC (human) or -5 oC (CVM-1) and terminated at times up to 60 s by 
the addition of 2 µL of 5% SDS (human) or 1% SDS (CVM-1). Assays were carried 
out in the absence of compound or in the presence of 100 µM etoposide. 
 All samples were processed and analyzed as described for plasmid DNA 
cleavage. The percent DNA cleavage at time 0 was set to 100% and the rate of 
religation was determined by quantifying the loss of cleaved DNA over time.  
 It should be noted that the religation activity of human topoisomerase IIα 
was examined by both methods described above with similar results. PBCV-1 
topoisomerase II religation activity was examined only by the first method 
described, because a shift to lower temperature does not promote religation. 
CVM-1 topoisomerase II religation activity was examined only by the second 
method described, because CaCl2 does not promote DNA cleavage by this type II 
enzyme.  
 
DNA Intercalation 
Intercalation reaction mixtures contained 220 nM topoisomerase IIα and 5 
nM pBR322 DNA in a total of 20 µL of relaxation buffer that contained 1 mM 
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ATP, 0–25 µM ethidium bromide, 0–500 µM amsacrine, or 0–200 µM TAS-103. 
Mixtures were incubated at 37 °C for 6 min, extracted with 
phenol:chloroform:isoamyl alcohol (25:24:1), and added to 3 µL of 0.77% SDS, 77 
mM EDTA (pH 8.0). Samples were mixed with 2 µL of agarose gel loading 
buffer, heated at 45 °C for 5 min, and subjected to electrophoresis in a 1% agarose 
gel in 100 mM Tris-borate (pH 8.3), 2 mM EDTA. Gels were stained with 1 
µg/mL ethidium bromide, and DNA bands were visualized as described for 
plasmid DNA cleavage.  
 The DNA intercalation assay is based on the fact that intercalative agents 
induce constrained negative supercoils and compensatory unconstrained 
positive superhelical twists in covalently closed circular DNA. Therefore, as the 
concentration of an intercalative compound increases, a plasmid that is 
negatively supercoiled or relaxed (i.e., contains no superhelical twists) appears to 
become positively supercoiled. Treatment of an intercalated plasmid with 
topoisomerase IIα removes the unconstrained positive DNA superhelical twists. 
Subsequent extraction of the compound allows the local drug-induced 
unwinding to redistribute in a global manner and manifest itself as a net 
negative supercoiling of the plasmid. Thus, in the presence of an intercalative 
agent, topoisomerase treatment converts relaxed plasmids to negatively 
supercoiled molecules (see insets, Figures 23 and 24). 
 
Construction of the hTop2αCTDβ and hTop2βCTDα Expression Vectors 
 The human topoisomerase IIβ gene in the YepWob6 plasmid was digested 
with KpnI and SalI restriction endonucleases. The resulting fragment of the 
topoisomerase IIβ gene was ligated using the same restriction sites into the 
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pUC18 expression plasmid. The Stratagene QuickChange II Site-directed 
Mutagenesis Kit was utilized to introduce an AvrII cut site at base 3159 (amino 
acid 1053) in the topoisomerase IIβ gene by PCR. The following sequences were 
used for the forward and reverse primers, respectively: 5’- 
GTTATTACGGTTTACGTAA-GGAGTGGCTCCTAGGAATGTTGGG - 3’ and 5’- 
CCCAACATTCCTAGGAGC-CACTCCTTACGTAAACCGTAATAAC- 3’. DNA 
was denatured at 95 oC for 5 min and subjected to 16 rounds of PCR using the 
following program: denaturation at 95 oC for 1 min, annealing at 55 oC for 1 min, 
and primer extension at 68 oC for 8 min. Following the last round of PCR, 
primers were allowed to extend for an additional 5 min at 68 oC. The final 
product was purified by agarose gel electrophoresis and transformed into XL1-
Blue E. coli cells. The purified plasmid was digested with KpnI and SalI and the 
topoisomerase IIβ fragment was ligated back into the original YepWob6 vector.  
 The human topoisomerase IIα gene in YepWob6 and the new topoisomerase 
IIβ gene both were digested with AvrII and XmaI, resulting in the isolation of 
each C-terminal domain fragment. Each C-terminal domain fragment and 
remaining vector fragment was gel purified. The isolated C-terminal domain 
fragments were then ligated to the opposite parent vector fragments and 
transformed into XL1-Blue E. coli cells. The C-terminal domain switched 
topoisomerase II constructs were sequenced to confirm the primary structures of 
the genes. The resulting plasmids carrying either hTop2αCTDβ or hTop2βCTDα 
were transformed in S. cerevisiae by heat shock.  
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CHAPTER III 
 
HUMAN TOPOISOMERASE IIα RAPIDLY RELAXES POSITIVELY 
SUPERCOILED DNA: IMPLICATIONS FOR ENZYME ACTION AHEAD OF 
REPLICATION FORKS 
 
 
Introduction 
 The movement of the replication machinery on DNA results in the 
accumulation of positive superhelical twists ahead of the fork and precatenanes 
behind (3,5-7,11). Although the torsional stress of DNA overwinding can be 
alleviated by the actions of an enzyme that generates single-stranded breaks in 
the double helix, the untangling of daughter chromosomes can only be 
accomplished by an enzyme that creates double-stranded breaks (5,7,12,14-
16,30). Thus, it has been assumed that topoisomerase I functions ahead of the 
replication fork, while topoisomerase II acts behind.  
 There are two lines of evidence suggesting that type II topoisomerases have 
normal physiological functions ahead of DNA tracking systems, such as the 
replication fork. First, yeast topoisomerase II can compensate for the loss of 
topoisomerase I in S. cerevisiae, but loss of both enzymes abruptly halts DNA 
synthesis (8,9). This finding indicates that the type II enzyme can assume the role 
of topoisomerase I ahead of the replication machinery. Second, E. coli 
topoisomerase IV (whose functions in bacteria appear to parallel those of 
topoisomerase II in eukaryotes) can partially compensate for the loss of DNA 
gyrase during replication elongation (211,212). Moreover, topoisomerase IV 
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relaxes positive DNA supercoils ~20–fold faster than it does negative supercoils 
(213,214).  
 If type II topoisomerases play a role ahead of replication forks in vertebrate 
species, then positively supercoiled DNA should be the preferred relaxation 
substrate for topoisomerase IIα, the isoform that is involved in replicative 
processes. Results indicate that human topoisomerase IIα relaxes positively 
supercoiled plasmids >10–fold faster than negatively supercoiled molecules. In 
contrast, human topoisomerase IIβ, which is not required for DNA replication, 
shows no such preferential relaxation. Finally, topoisomerase IIα maintains lower 
levels of DNA cleavage complexes with positively supercoiled molecules. These 
enzymological properties are consistent with a topoisomerase that functions 
ahead of the replication machinery. 
 
Results 
 
Generation of Positively Supercoiled DNA Substrates 
 Steady-state interactions between eukaryotic topoisomerases and positively 
supercoiled DNA molecules have been examined previously (67,111,215-217). 
However, in most cases, positive superhelical twists were introduced in the DNA 
by the addition of intercalating agents such as ethidium bromide or chloroquine 
(67,111,215,216). Since these chemicals locally underwind the double helix, they 
generate a compensatory global overwinding elsewhere in covalently closed 
circular DNA substrates. Although previous studies have provided useful 
information, they suffer from a common deficiency; it is not always possible to 
dissociate the effects of DNA topology on topoisomerase action from those of the 
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intercalating agent. Thus, these studies have not been able to assess interactions 
between eukaryotic topoisomerases and positively supercoiled DNA in a 
quantitative manner. 
 To overcome this critical deficiency, we prepared positively supercoiled 
molecules by incubating pBR322 plasmid DNA with A. fulgidus reverse gyrase. 
This type IA topoisomerase is the only enzyme unique to hyperthermophiles and 
the only known topoisomerase that can actively introduce positive superhelical 
twists into DNA (206,218-221).   
 A time course for the conversion of negatively to positively supercoiled 
pBR322 DNA is shown in Figure 10. The initial plasmid substrate contained ~15 
to 17 negative superhelical twists per molecule (σ ≈ -0.035 to –0.039) as 
determined by electrophoretic band counting in agarose gels containing 
chloroquine. This superhelical density is typical of plasmids isolated from E. coli. 
Reverse gyrase rapidly relaxed pBR322 and positive superhelical twists began to 
appear within the first minute of the reaction. As determined by electrophoretic 
band counting in gels containing netropsin B, positively supercoiled plasmids 
generated following a 5 min incubation with reverse gyrase contained ~15 to 17 
positive superhelical twists per molecule (σ ≈ +0.035 to +0.039). The handedness 
of positively supercoiled DNA was confirmed by two-dimensional gel 
electrophoresis (Figure 11, left panel). Thus, the substrates employed for the 
experiments in this study contained equivalent numbers of superhelical twists, 
but were of opposite handedness. 
 When resolved by one-dimensional gel electrophoresis, relaxation mixtures 
were run in the absence of intercalating dyes and subsequently stained with 
ethidium bromide. Despite the opposite handedness of the DNA substrates  
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Figure 10. Generation of positively supercoiled DNA by A. fulgidus reverse 
gyrase. The positions of negatively (-) supercoiled, relaxed and positively (+) 
supercoiled DNA are indicated. Negatively supercoiled pBR322 plasmid DNA 
was incubated with reverse gyrase for the indicated times. The extent of positive 
supercoiling was monitored by agarose gel electrophoresis.  
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Figure 11. Two-dimensional gel electrophoresis of negatively and positively 
supercoiled DNA relaxation by human topoisomerase IIα. Ethidium bromide-
stained agarose gels displaying representative relaxation reactions of negatively 
supercoiled [(-) SC] or positively supercoiled  [(+) SC] pBR322 plasmid DNA by 
human topoisomerase IIα are shown. The positions of negatively supercoiled, 
positively supercoiled, and nicked circular DNA in the absence of enzyme are 
shown in the left panel. Relaxation of negatively supercoiled DNA after 30 min is 
shown in the center panel. Relaxation of positively supercoiled DNA after 5 min 
is shown in the right panel. The positions of fully relaxed DNA products are 
indicated (Relaxed). 
 
1D 
2D 
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employed, similar resolution of negatively and positively supercoiled plasmids 
was observed. However, it is notable that positively supercoiled substrates bind 
less ethidium bromide than negatively supercoiled plasmids. Therefore, to 
ensure that equal amounts of initial substrates were used in all experiments, 
DNA concentration was independently assessed by spectrophotometric analysis 
and by ethidium bromide staining of linearized plasmid substrates (see insets, 
Figures 12 and 17).  
 
Human Topoisomerase IIα Preferentially Relaxes Positively Supercoiled DNA 
 If type II topoisomerases play a role ahead of replication forks in vertebrates, 
then positively supercoiled DNA might be the preferred relaxation substrate for 
topoisomerase IIα, the isoform that is involved in replicative processes. 
Therefore, to characterize interactions between human topoisomerase IIα and 
DNA substrates found ahead of replication forks, we assessed the ability of the 
enzyme to relax positively supercoiled molecules (Figures 11 and 12). 
 Compared to relaxation of negatively supercoiled substrates, the enzyme 
removed positive superhelical twists at a much higher rate. In addition, 
topoisomerase IIα relaxed positive supercoils in a more distributive fashion. 
Because of this difference, relaxation rates were quantified by one-dimensional 
gel analysis using two complementary methods: gain of fully relaxed product or 
loss of fully supercoiled substrate (Figure 12). As determined by the former 
method, the rate of relaxation of positively supercoiled DNA by topoisomerase 
IIα is >30–fold higher than the rate of relaxation of negatively supercoiled 
molecules. As determined by the latter method, it is nearly 10–fold higher.  
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Figure 12. Human topoisomerase IIα relaxes positively supercoiled DNA faster 
than negatively supercoiled molecules. Ethidium bromide-stained agarose gels 
displaying representative time courses for relaxation of negatively supercoiled [(-) 
SC; top gel] or positively supercoiled  [(+) SC; bottom gel] pBR322 plasmid DNA by 
human topoisomerase IIα are shown. Relaxed DNA standards (Std) were 
generated by incubation with 20 nM enzyme for 60 min. The positions of 
supercoiled plasmid DNA (form I, FI) and relaxed DNA (form II, FII) are 
indicated. DNA relaxation was quantified from either the gain of fully relaxed 
product (left panel) or the loss of supercoiled substrate (right panel). Error bars 
represent the standard error of the mean of two independent assays. Positively 
supercoiled DNA binds less ethidium bromide than does negatively supercoiled 
DNA. To demonstrate that equal amounts of the two substrates were employed 
in assays, linear digests of the plasmids are shown in the inset. Supercoiled 
plasmid DNA (form 1, FI) and linear molecules (form III, FIII) are indicated.  
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 Similar differences in relaxation rates were observed when reaction mixtures 
were resolved by two-dimensional gel electrophoresis (Figure 11). The center 
panel shows the results of a 30 min relaxation assay with negatively supercoiled 
plasmid, and the right panel shows a 5 min assay with positively supercoiled 
substrate. It should be noted that as the DNA molecules approached their fully 
relaxed state, underwound plasmids remained slightly negatively supercoiled 
and overwound plasmids remained slightly positively supercoiled. However, 
since the buffer conditions of the DNA relaxation assays and the gel 
electrophoresis are not identical, it is possible that the final distribution of 
reaction products differs somewhat. 
 The degree of DNA overwinding that occurs ahead of DNA replication forks 
in human cells is not known. However, single molecule experiments suggest that 
DNA ahead of tracking systems can reach a σ value as high as +0.110 (222). DNA 
buckling (i.e., the transition to non-B-form structures) was not observed in these 
experiments below a σ value of +0.058 (222). Therefore, we believe that the 
positively supercoiled substrates used in our DNA relaxation assays (σ ≈ +0.035 
to +0.039) should be free of unusual non-B structures. 
 The salt concentration utilized for DNA relaxation experiments, 175 mM 
KCl, represents the optimal condition for the relaxation of negatively supercoiled 
substrates.  To determine whether the switch from a processive to a distributive 
reaction contributed to the preferential relaxation of positively supercoiled 
plasmids, additional assays were carried out at lower ionic strengths.  The 
relaxation of positively supercoiled DNA switched to a fully processive reaction 
at 100 mM KCl (Figure 13). Even under fully processive relaxation conditions, 
positively supercoiled DNA substrates were relaxed at a rate that was ~10-fold  
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Figure 13. Human topoisomerase IIα relaxes positively supercoiled DNA faster 
than negatively supercoiled DNA under processive conditions. Ethidium 
bromide-stained agarose gels displaying representative time courses for 
relaxation of negatively supercoiled [(-) SC; top gel] or positively supercoiled  [(+) 
SC; bottom gel] pBR322 plasmid DNA by human topoisomerase IIα in 100 mM KCl 
are shown. The positions of supercoiled plasmid DNA (form I, FI) and relaxed 
DNA (form II, FII) are indicated. Since reactions with both substrates were 
processive, DNA relaxation was quantified by the loss of supercoiled substrate. 
Error bars represent the standard deviation of four independent assays. 
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faster than that observed with negatively supercoiled plasmids. Therefore, the 
processivity of DNA relaxation by human topoisomerase IIα does not appear to 
be the underlying basis for the preferential removal of positive superhelical 
twists. 
 
Human Topoisomerase IIβ Does Not Preferentially Relax Positively Supercoiled DNA 
  Although topoisomerase IIα and β differ dramatically in their physiological 
regulation and functions, the two isoforms display only minimal differences in 
their enzymatic properties (15,16,33,35,223). Since topoisomerase IIβ is not 
believed to play a role in DNA replication, it was of interest to determine 
whether this isoform also displayed a preference for positively supercoiled 
molecules. As seen in Figure 14, topoisomerase IIβ relaxed positive and negative 
DNA supercoils at similar rates (less than 2–fold difference). Once again, 
relaxation of positively supercoiled molecules appeared to be more distributive. 
The recognition of positively supercoiled DNA by topoisomerase IIα represents 
the first major enzymological difference between the two isoforms. Furthermore, 
it is consistent with the proposal that topoisomerase IIα, and not topoisomerase 
IIβ, functions in DNA replication.   
 
Effects of DNA Supercoil Geometry on Substrate Binding by Human Topoisomerase IIα 
 Previous studies indicate that the ability of human topoisomerase IIα to 
recognize DNA sequence or damage is controlled by chemical steps in the 
catalytic cycle of the enzyme rather than by alterations in substrate binding 
affinity (210,224,225). In contrast, the ability of eukaryotic type II topoisomerases 
to distinguish negatively supercoiled DNA from relaxed substrates appears to be  
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Figure 14. Human topoisomerase IIβ does not preferentially relax positively 
supercoiled DNA. Ethidium bromide-stained agarose gels displaying 
representative time courses for relaxation of negatively supercoiled [(-) SC; top 
gel] or positively supercoiled  [(+) SC; bottom gel] pBR322 plasmid DNA by human 
topoisomerase IIβ are shown. The positions of supercoiled DNA (form I, FI) and 
relaxed DNA (form II, FII) are indicated. DNA relaxation was quantified from 
either the gain of fully relaxed product (left panel) or the loss of supercoiled 
substrate (right panel). Error bars represent the standard error of the mean or 
standard deviation of two or three independent assays, respectively. 
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governed primarily by binding interactions (67,69,215,226). These enzymes 
differentiate between supercoiled and relaxed DNA topoisomers by 
preferentially interacting with DNA crossovers, which are more prevalent in 
supercoiled molecules (69,215). However, since both negatively and positively 
supercoiled molecules contain DNA nodes, albeit of opposite handedness, it is 
not known how topoisomerase IIα discriminates between underwound and 
overwound DNA. 
 As a first step towards addressing this critical issue, the relative affinity of 
the human enzyme for negatively and positively supercoiled plasmids was 
determined using a competitive DNA binding assay (Figure 15). In this system, 
the ability of supercoiled plasmids to compete with radiolabeled linear pBR322 
molecules for binding to topoisomerase IIα was monitored on nitrocellulose 
filters. The enzyme was exposed to both DNA substrates simultaneously, and the 
6 min time point used for the assay ensured that a binding equilibrium was 
established. DNA binding was analyzed at the two salt conditions, 175 and 100 
mM KCl, used for DNA relaxation assays.  
 At either ionic strength, topoisomerase IIα displayed a slightly higher 
affinity (~2–fold) for negatively supercoiled plasmids as compared to positively 
supercoiled substrates (Figure 15). This finding indicates that the rapid relaxation 
of positively supercoiled molecules by human topoisomerase IIα is not due to a 
higher binding affinity of the enzyme for its initial DNA substrate. 
 
Effects of DNA Supercoil Geometry on ATP Hydrolysis by Human Topoisomerase IIα 
 DNA-bound topoisomerase II hydrolyzes more ATP than does free enzyme 
(67,84,227-230). It has been proposed that the stimulation of ATP hydrolysis by 
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Figure 15. Binding of human topoisomerase IIα to negatively and positively 
supercoiled DNA. The ability of 0–20 nM negatively supercoiled [(-) SC] or 
positively supercoiled [(+) SC] pBR322 plasmid DNA to compete with the 
binding of 5 nM [32P]-labeled linear pBR322 DNA by human topoisomerase IIα is 
shown. Percent linear DNA bound was determined by the ratio of cpm retained 
on a nitrocellulose filter vs. the input amount of radioactivity. Error bars represent 
the standard deviation of three independent assays. 
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 DNA represents a non-productive cycling of the enzyme in the “closed-clamp” 
form and actually decreases the efficiency of ATP utilization (230).  Therefore, if 
topoisomerase IIα relaxes positively supercoiled substrates more efficiently than 
it does negatively supercoiled DNA, it might hydrolyze lower levels of ATP 
during the course of the reaction. As seen in Figure 16, the rate of ATP hydrolysis 
in the presence of positively supercoiled plasmid was ~2–fold lower than the rate 
observed in reactions that contained negatively supercoiled DNA.  
 
Human Topoisomerase IIα and β Maintain Lower Levels of DNA Cleavage Complexes 
with Positively Supercoiled Substrates 
 
 As a prerequisite to the strand passage event, topoisomerase II creates 
transient double-stranded breaks in its DNA substrate. To maintain genomic 
integrity during this process, the enzyme forms covalent bonds between active 
site tyrosyl residues and the 5’-terminal phosphates of the cleaved DNA 
(5,15,16,30,51). However, two negative outcomes are possible if a DNA tracking 
system, such as the replication machinery, collides with one of these cleavage 
complexes. First, the collision can disrupt the cleavage complex, making it 
impossible for the enzyme to ligate the cleaved strands (198,231). Second, the 
collision can arrest the progress of the replication fork, which triggers fork restart 
and recombination pathways (88). Both of these outcomes eventually lead to the 
formation of double-stranded breaks in the genome (15,16,76,196-198,232). 
 Since the DNA that precedes the replication fork is overwound, we 
characterized the ability of human topoisomerase IIα and β to cleave positively 
supercoiled plasmid molecules (Figure 17 and 18, respectively). Over a range of 
enzyme:plasmid ratios, levels of DNA scission by topoisomerase IIα were 3– to  
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Figure 16. Hydrolysis of ATP by human topoisomerase IIα in the presence of 
negatively and positively supercoiled DNA. A time course for the hydrolysis of 
ATP in the presence of negatively supercoiled [(-) SC] or positively supercoiled 
[(+) SC] pBR322 plasmid DNA is shown. ATPase activity was monitored by 
quantifying the release of free phosphate from [γ-32P]ATP. Error bars represent 
the standard deviation of three independent assays. 
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Figure 17. Human topoisomerase IIα maintains lower levels of DNA cleavage 
complexes with positively supercoiled DNA than with negatively supercoiled 
molecules. Left, the ability of 0–800 nM human topoisomerase IIα to cleave 
negatively supercoiled  [(-) SC] pBR322 plasmid DNA or positively supercoiled 
[(+) SC] molecules is shown. Assays employed Mg2+ as the divalent cation. Error 
bars represent the standard deviation of three to four independent experiments. 
The inset shows a representative ethidium bromide-stained agarose gel of DNA 
cleavage assays that utilized either Mg2+ or Ca2+ as the divalent cation. 
Supercoiled DNA from reactions that lacked topoisomerase IIα (-TII) and a linear 
(Lin) DNA standard are shown. The positions of supercoiled (form I, FI), nicked 
circular (form II, FII), and linear molecules (form III, FIII) are indicated. Right, 
DNA sites cleaved by human topoisomerase IIα were mapped in negatively 
supercoiled or positively supercoiled plasmid substrates. Reaction products are 
representative of three independent experiments. Reactions utilized either Mg2+ 
or Ca2+ as the divalent cation. DNA from reactions that lacked topoisomerase IIα 
(-TII) are shown. 
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4–fold lower with positively supercoiled substrates than observed with 
negatively supercoiled plasmids. Similar results were seen when the 
physiological divalent cation, Mg2+, was replaced with Ca2+ (Figure 17, inset). This 
latter divalent cation supports higher levels of DNA cleavage (73,74). Although 
DNA scission was reduced with overwound substrates, the site specificity of 
cleavage, as well as the relative site utilization, was identical with positively and 
negatively supercoiled DNA (Figure 17).  
 In contrast to relaxation assays, DNA cleavage results were similar for 
topoisomerase IIα and β. Topoisomerase IIβ maintained lower (~3– to 4–fold) 
levels of cleavage complexes with positively supercoiled DNA as compared to 
negatively supercoiled substrates (Figure 18). These results suggest that the 
human type II enzyme utilizes two distinct mechanisms to distinguish supercoil 
geometry during DNA relaxation and cleavage. This hypothesis will be 
discussed further in chapter V of this dissertation. 
  
Discussion 
 Previous in vivo studies on S. cerevisiae topoisomerase II (8,9) and E. coli 
topoisomerase IV (211,212) suggest a role for type II enzymes ahead of the 
replication fork. This suggestion is supported by in vitro studies, which indicate 
that topoisomerase IV preferentially relaxes positively supercoiled DNA 
(213,214). To determine whether mammalian type II topoisomerases also display 
catalytic properties consistent with functions ahead of a replication fork, we 
characterized the ability of human topoisomerase IIα and β to relax positively 
supercoiled DNA.  
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Figure 18. Human topoisomerase IIβ maintains lower levels of DNA cleavage 
complexes with positively supercoiled DNA than with negatively supercoiled 
molecules. The ability of 0- 1 µM topoisomerase IIβ to cleave negatively [(-)SC, 
open circles] or positively [(+)SC, closed circles] supercoiled pBR322 plasmid 
DNA is shown. Error bars represent the standard deviation of four independent 
assays.  
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 Topoisomerase IIα displayed two important enzymological characteristics 
that would be beneficial to an enzyme that operates ahead of the replication 
machinery. First, the enzyme removed positive superhelical twists at a rate that 
was >10–fold faster than it did negative superhelical twists. Thus, topoisomerase 
IIα displays preferential activity with the DNA substrates that accumulate ahead 
of the fork. Furthermore, the rapid rate of catalysis with overwound substrates 
makes it less likely that the replication machinery would collide with a molecule 
of topoisomerase IIα acting on the pre-replicated DNA. Second, the enzyme 
maintained lower levels of DNA cleavage complexes with positively supercoiled 
substrates. This decreases the probability that a collision with a replication fork 
would result in the formation of a topoisomerase II-associated double-stranded 
break in the genetic material. Taken together, these properties suggest that 
human topoisomerase IIα has the potential to alleviate torsional stress ahead of 
replication forks in an efficient and safe manner. 
 In contrast to the α isoform, topoisomerase IIβ, which is not believed to 
function in DNA replication, relaxed positively and negatively supercoiled 
substrates at similar rates. Relatively few studies on the enzymatic properties of 
topoisomerase IIβ have been reported. However, in every fundamental 
mechanistic aspect that has been compared, topoisomerase IIα and β are virtually 
identical (33,35,223). Results of the present study indicate a major difference 
between these two isoforms that is consistent with their proposed physiological 
roles. It is not clear how topoisomerase IIα, but not β, is able to distinguish 
supercoil geometry during DNA relaxation. However, based on structural 
studies on DNA gyrase and topoisomerase IV, coupled with nucleic acid 
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modeling and binding experiments, it has been proposed that this ability resides 
in the C-terminal domain of bacterial type II enzymes (62-64,217).  
 The amino acid sequence of the C-terminal domain varies considerably from 
species to species. Although topoisomerase IIα and β possess a high degree of 
amino acid sequence identity in their catalytic cores (~79% identity), the two 
enzymes diverge considerably in their C-terminal domains (~31% identity) (233). 
The present observations make it tempting to speculate that the C-terminal 
domain of human topoisomerase IIα plays a role in sensing the geometry of 
DNA substrates. Studies with deletion mutants of the human enzyme currently 
are underway to test this hypothesis. 
 In contrast to DNA relaxation assays, topoisomerase IIα and β both 
displayed lower levels of DNA cleavage with positively supercoiled substrates. 
The results suggest a bimodal recognition of DNA geometry by human type II 
topoisomerases. This idea will be discussed in depth in chapter V of this 
disseration. 
  Lower eukaryotic species, such as S. cerevisiae and Drosophila contain only 
one isoform of topoisomerase II (31,32). Single molecule experiments suggest that 
Drosophila topoisomerase II removes DNA supercoils of different handedness at 
similar rates (217). Steady-state experiments conducted as part of the present 
work support this conclusion (Figure 19). Drosophila topoisomerase II relaxed 
positively supercoiled plasmids at a rate that was marginally (<2–fold) higher 
than obtained with negatively supercoiled molecules (Figure 19, left panel). 
Similar results were observed with S. cerevisiae topoisomerase II, which relaxed 
positively supercoiled plasmids ~2 to 3 times faster (Figure 19, right panel). It is 
not known why the ability to discern the handedness of DNA supercoils is not  
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Figure 19. Drosophila and yeast topoisomerase II display similar relaxation 
rates with negatively and positively supercoiled DNA. Time courses for 
relaxation of negatively supercoiled [(-) SC] or positively supercoiled  [(+) SC] 
pBR322 plasmid DNA by Drosophila topoisomerase II (left panel) or yeast 
topoisomerase II (right panel) are shownDNA relaxation was quantified from 
either the loss of supercoiled substrate. Error bars represent the standard 
deviation or standard error of the mean of three or two independent assays, 
respectively. 
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extended (or is weakly extended) to eukaryotic organisms that contain only a 
single isoform of topoisomerase II. However, it may be related to the distinct 
separation of physiological functions of topoisomerase IIα and β in vertebrate 
species. 
 Human topoisomerase IIα and E. coli topoisomerase IV (213,214) both 
preferentially relax positively supercoiled DNA. Although neither enzyme 
displays an increased affinity for positive DNA supercoils, they exhibit different 
attributes with overwound molecules with regard to DNA cleavage. Whereas 
topoisomerase IIα maintains lower levels of cleavage complexes with positively 
supercoiled substrates, topoisomerase IV displays higher amounts of DNA 
scission (213). Thus, there appears to be at least one fundamental difference 
between the modalities these two enzymes use to distinguish the handedness of 
superhelical twists.  
 In summary, human topoisomerase IIα preferentially removes positive 
superhelical twists from DNA. This finding suggests that positively supercoiled 
DNA is the preferred physiological substrate for this enzyme and implies that 
topoisomerase IIα plays a role in relieving torsional stress that accumulates in 
front of the replication machinery or other DNA tracking systems. The high rates 
of DNA relaxation observed with positively supercoiled substrates, coupled with 
the low levels of DNA cleavage, makes topoisomerase IIα ideally suited to 
function ahead of replication forks. 
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CHAPTER IV 
 
GEOMETRY OF DNA SUPERCOILS MODULATES TOPOISOMERASE-
MEDIATED DNA CLEAVAGE AND ENZYME RESPONSE TO ANTICANCER 
DRUGS 
 
 
Introduction 
 Humans encode three different type I topoisomerases, topoisomerase I, IIIα, 
and IIIβ (17,234-237). Of these enzymes, only topoisomerase I currently is 
exploited for cancer chemotherapy (17,19,26). This enzyme is the target for an 
emerging class of drugs based on the parent compound, camptothecin 
(17,19,26,27). One important aspect of topoisomerase I-targeted agents is that 
they are active against a spectrum of cancers that currently have few, if any, 
other treatment options.  
 Type II topoisomerases are targets for a number of well-established 
chemotherapeutic agents (15-19,90-92). One of these drugs, etoposide, has been 
used in the clinic since the 1960’s (91,92,94). It is prescribed as treatment for a 
wide spectrum of leukemias, lymphomas, and solid tumors. The relative 
contributions of topoisomerase IIα and β to therapeutic outcomes are not clear at 
the present time. However, drug interactions with topoisomerase IIβ in 
differentiated tissues, such as heart, are believed to contribute to the dose-
limiting toxicity of some agents (95-98). 
 Although topoisomerase-targeted anticancer drugs come from several 
different structural classes, they all act by increasing levels of covalent 
topoisomerase-cleaved DNA complexes (i.e., cleavage complexes) that are 
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requisite intermediates in the catalytic cycles of these enzymes (15,16,19,89,90). 
Cleavage complexes are transient in nature. However, they are converted to 
permanent DNA strand breaks when nucleic acid tracking systems, such as 
replication or transcription complexes, attempt to traverse these covalent 
topoisomerase-DNA roadblocks in the genetic material (15,16,19,89,90). The 
resulting strand breaks, as well as the inhibition of essential DNA processes, 
initiate multiple recombination/repair pathways (15,16,76-78). If the 
accumulation of strand breaks becomes overwhelming, they trigger cell death 
pathways (77).   
 Despite the importance of DNA tracking enzymes to drug efficacy, 
relationships between the geometry of DNA supercoils and the activity of 
topoisomerase-targeted anticancer agents have not been characterized. Thus, the 
ability of drugs to induce DNA cleavage mediated by human topoisomerase IIα, 
topoisomerase IIβ, and topoisomerase I was assessed with positively supercoiled 
substrates. Results indicate that the geometry of DNA supercoils can 
significantly diminish or enhance the actions of anticancer drugs in an enzyme-
dependent manner. Additionally, results provide an explanation for the 
differential effects of intercalative and non-intercalative drugs on DNA scission 
mediated by type II topoisomerases. 
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Results 
 
Effects of DNA Supercoil Geometry on Drug-induced DNA Cleavage Mediated by 
Human Topoisomerase IIα.  
 
 Collisions with DNA tracking systems are critical for the conversion of 
transient topoisomerase-DNA cleavage complexes to permanent strand breaks 
(15,16,19,89,90). Since the double helix is acutely overwound immediately ahead 
of tracking systems (3,5-7,11,238-240), cleavage complexes most likely to produce 
permanent strand breaks should be formed between topoisomerases and 
positively supercoiled DNA. Unfortunately, relatively little is known about the 
interaction between these enzymes and positively supercoiled substrates. 
 Data in chapter III demonstrated that human topoisomerase IIα maintains a 
lower concentration of DNA cleavage complexes with overwound than with 
underwound substrates. Levels of DNA cleavage mediated by topoisomerase IIα 
in the presence of either Mg2+ or Ca2+ are ~3– to 4–fold lower with positively 
supercoiled DNA (Figures 17 and 20). The decreased baseline levels of DNA 
cleavage observed with overwound DNA may reflect, at least in part, somewhat 
lower binding affinity (~2–fold) that topoisomerase IIα displays for positively 
over negatively supercoiled molecules (Figure 15). The lower level of cleavage 
notwithstanding, the site specificity of DNA scission is not affected by the 
handedness of the substrate (Figures 17 and 20, right panels). 
 Many anticancer drugs kill cells by increasing levels of double-stranded 
DNA breaks generated by topoisomerase II (15,16,19,89,90). As a first step 
towards characterizing the effects of these drugs on enzyme-DNA cleavage 
complexes formed with positively supercoiled substrates, the ability of etoposide  
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Figure 20. Human topoisomerase IIα maintains lower levels of DNA cleavage 
complexes with positively supercoiled plasmids in the absence or presence of 
etoposide. The ability of topoisomerase IIα to cleave negatively [(-)SC, open 
circles] or positively [(+)SC, closed circles] supercoiled pBR322 plasmid DNA in 
the presence of 0–100 µM etoposide is shown (left panel). Assays employed Mg2+ 
as the divalent cation. Error bars represent the standard deviation of four 
independent assays. The inset shows a representative ethidium bromide-stained 
agarose gel of DNA cleavage assays with negatively and positively supercoiled 
plasmids in the absence of topoisomerase IIα (-TII) and in the absence (no drug, 
ND) or presence (Etop) of etoposide. Linear DNA standards (Lin) also are shown. 
The positions of supercoiled (form I, FI), nicked circular (form II, FII), and linear 
molecules (form III, FIII) are indicated. DNA sites cleaved by topoisomerase IIα 
were mapped in negatively or positively supercoiled plasmids (right panel). 
Products of DNA cleavage assays were linearized and singly-end labeled with 
[32P]phosphate. The autoradiogram is representative of three independent assays. 
Reactions were carried out in the presence of 0 or 100 µM etoposide, and utilized 
either Mg2+ or Ca2+ as the divalent cation. DNA from reactions that lacked 
topoisomerase IIα (-TII) are shown. 
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to induce DNA cleavage by human topoisomerase IIα was assessed. Etoposide 
was chosen for initial experiments because its mechanism of action is well 
defined (15,16,94,115,116,119,241). In addition, the drug is not intercalative in 
nature and displays little, if any, affinity for DNA (15,16,94,241,242). Over a 
range of drug concentrations, DNA cleavage induced by etoposide was ~3– to 4–
fold lower with positively as compared to negatively supercoiled molecules 
(Figure 20). Moreover, as observed in the absence of drug, the geometry of DNA 
supercoils did not affect the site specificity of etoposide-induced scission (Figure 
20, right panel). 
 Etoposide increases levels of topoisomerase II-DNA cleavage complexes 
primarily by inhibiting the ligation of cleaved strands (15,16,93,114,115). 
Therefore, the effects of etoposide on the ability of topoisomerase IIα to ligate 
positively or negatively supercoiled molecules were determined. As seen in 
Figure 21, the handedness of superhelical twists had little impact on rates of 
DNA ligation in either the presence or absence of etoposide. Thus, the decreased 
levels of DNA strand breaks induced by etoposide in positively supercoiled 
substrates do not result from a decreased inhibition of ligation. 
 Despite the lower absolute percent DNA cleaved with positively supercoiled 
substrates, the relative enhancement of scission by etoposide with overwound 
and underwound substrates was similar. For example, at 50 µM drug, this 
enhancement was ~4.5–fold and ~3.6-fold for positively and negatively 
supercoiled DNA, respectively (Figures 20 and 22, Table 1). These data yield a 
“superhelical specificity” for etoposide (i.e., relative cleavage enhancement 
observed with positively supercoiled DNA divided by the relative cleavage 
enhancement with negatively supercoiled DNA) of ~1.3 (Table 1). It should be  
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Figure 21. Etoposide inhibits the ligation of negatively or positively 
supercoiled DNA by human topoisomerase IIα. A time course of ligation in the 
presence of negatively [(-)SC, open symbols] or positively [(+)SC, closed symbols] 
supercoiled pBR322 plasmid is shown. DNA ligation was monitored in the 
absence (boxes) or presence (circles) of 100 µM etoposide (+Etop).  The initial 
level of DNA cleavage was set to 100% and the rate of ligation was determined by 
quantifying the loss of the cleaved DNA over time. Error bars represent the 
standard deviation of three independent assays. 
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noted that the superhelical specificity for etoposide varied little (1.0–1.3) over the 
entire range of drug concentration examined. These correlations, together with 
the ligation and site-specificity data, imply that interactions between etoposide 
and topoisomerase IIα are not altered significantly by the handedness of DNA. 
Rather, the decrease in drug-induced cleavage of positively supercoiled DNA 
reflects the reduced baseline (i.e., non-drug) level of enzyme-mediated scission 
with this substrate.  
 In light of this finding, the influence of DNA geometry on the actions of 
other topoisomerase II-targeted drugs, including, TOP-53, genistein, CP-115,953, 
TAS-103 and amsacrine, was characterized. These drugs are described in detail in 
chapter I of this dissertation. 
  All of the above compounds increased DNA cleavage mediated by human 
topoisomerase IIα. Data for 50 µM drugs are shown in Figure 22 and Table 1. The 
only exception is CP-115,953, for which data are shown for 5 µM drug (higher 
drug concentrations were not used because they induced multiple DNA cleavage 
events per plasmid). As found for etoposide, most induced higher absolute levels 
of scission with negatively supercoiled substrates, but displayed greater relative 
cleavage enhancement with positively supercoiled DNA. The non-intercalative 
drugs displayed superhelical specificities between 1.3 and 1.8. These values 
remained constant from the lowest drug concentrations examined (5 or 10 µM) 
up to concentrations that induced multiple DNA cleavage events per plasmid (50 
or 100 µM). It was not possible to determine superhelical specificities for CP-
115,953 above 5 µM due to the reason discussed above. Taken together, these 
results suggest that the superhelical specificity for DNA cleavage with non-
intercalative topoisomerase II poisons is independent of drug concentration. 
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Figure 22. Effects of DNA superhelical geometry on drug-induced DNA 
cleavage mediated by human topoisomerase IIα. The ability of topoisomerase 
IIα to cleave negatively [(-)SC DNA, open bars] or positively [(+)SC DNA, closed 
bars] supercoiled pBR322 plasmid DNA in the presence of various topoisomerase 
II-targeted drugs is shown. All drugs were used at a concentration of 50 µM, 
except for CP-115,953, which was used at 5 µM (multiple DNA cleavage events 
per plasmid were observed at higher concentrations of CP-115,953). Error bars 
represent the standard deviation of 3 or 4 independent assays. 
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Table 1. Relative DNA cleavage enhancement of human topoisomerase IIα by 
anticancer agents. 
 
Druga Relative Cleavage 
Enhancement  
(-)SC DNA 
Relative Cleavage 
Enhancement 
(+)SC DNA 
Superhelical 
Specificity 
[(+)SC/(-)SC] 
Etoposide 3.6 ± 0.4 4.5 ± 0.4 1.3 
TOP-53 5.4 ± 0.5 9.8 ± 1.1 1.8 
Genistein 3.7 ± 0.4 5.7 ± 0.5 1.5 
CP-115,953 3.2 ± 0.2 4.4 ± 0.6 1.4 
TAS-103 1.1 ± 0.1 7.8 ± 0.9 7.1 
Amsacrine 7.5 ± 0.3 22.6 ± 0.7 3.0 
 
 aAll drugs were at 50 µM, with the exception of CP-115-953, which was at 
5 µM (multiple DNA cleavage events per plasmid were observed at higher 
concentrations of CP-115,953). 
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 The superhelical specificities of the two intercalative drugs (TAS-103 and 
amsacrine) at 50 µM, 7.1 and 3.0, respectively, were greater than those seen for 
the non-intercalative compounds. These higher values suggest that DNA 
geometry may influence the actions of intercalative compounds towards 
topoisomerase IIα beyond their effects on baseline DNA cleavage mediated by 
the enzyme.  
 Drugs that target topoisomerases are believed to work at the enzyme-nucleic 
acid interface (15,16,119-124). However, intercalative agents have two additional 
effects on DNA that could impact levels of topoisomerase-mediated scission in a 
geometry-specific manner. First, since these compounds locally underwind 
DNA, they induce compensatory unconstrained positive superhelical twists in 
distal regions of covalently closed circular molecules (125,126). Thus, as the 
concentration of an intercalating agent increases, a plasmid that is topologically 
negatively supercoiled would appear to contain positive superhelical twists. As 
discussed above, baseline levels of DNA cleavage mediated by topoisomerase IIα 
are lower with positively supercoiled substrates. Consequently, the apparent 
change in DNA topology induced by intercalation could diminish the ability of a 
compound to enhance cleavage with underwound substrates. In contrast, the 
apparent geometry of a positively supercoiled plasmid (which already is 
overwound) would not change substantially upon addition of an intercalative 
drug.  
 Second, the accumulation of drugs in the double helix has the potential to 
inhibit enzyme binding or activity. Because the generation of positive 
superhelical twists by DNA intercalation induces torsional stress in the double 
helix, the ability of covalently closed molecules to absorb these compounds is 
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limited. Since overwound plasmids are under positive torsional stress even in the 
absence of drugs, they cannot bind as many intercalative molecules as 
underwound DNA. Therefore, enzyme activity on positively supercoiled 
substrates is less likely to be inhibited by the accumulation of bound drug. 
 Two independent experiments were carried out to determine whether the 
above effects contribute to the higher superhelical specificity of intercalative 
agents. The first utilized ethidium bromide, a classical intercalating agent that 
does not enhance topoisomerase II-mediated DNA scission. When ethidium 
bromide was included in reaction mixtures, there was a precipitous drop in the 
ability of human topoisomerase IIα to cleave negatively supercoiled pBR322 
(Figure 23). Levels of cleavage decreased ~6–fold at 10 µM ethidium bromide, 
which corresponds to the concentration at which “full” intercalation was 
observed (see inset). Beyond 10 µM, little additional inhibition was observed. 
Thus, the decrease in DNA cleavage induced by ethidium bromide correlates 
with the change in the apparent supercoiled state of the plasmid substrate. 
Consistent with this conclusion, ethidium bromide had a much smaller effect on 
DNA cleavage when the initial substrate was positively supercoiled (Figure 23). 
Furthermore, once the concentration of ethidium bromide exceeded 10 µM, DNA 
cleavage levels for positively and negatively substrates were virtually identical.  
 To determine whether ethidium bromide accumulation on the double helix 
affects the DNA cleavage activity of topoisomerase IIα independent of changes in 
DNA geometry, a linear substrate was employed (Figure 23, right panel). Since 
linear molecules are not topologically constrained, DNA intercalation does not 
induce torsional stress or positive supercoiling in these substrates. The addition 
of 10 µM ethidium bromide only had a minor effect on levels of DNA cleavage  
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Figure 23. Effects of ethidium bromide intercalation on DNA cleavage 
mediated by human topoisomerase IIα. The ability of topoisomerase IIα to 
cleave negatively [(-)SC, open circles] or positively [(+)SC, closed circles] 
supercoiled pBR322 plasmid DNA in the presence of 0–25 µM ethidium bromide 
is shown (left panel). Error bars represent the standard deviation of three 
independent assays. The inset shows a representative gel of DNA intercalation 
assays using negatively supercoiled plasmids in the absence of topoisomerase IIα 
(-TII), or in the absence (0 µM) or presence (1–25 µM) of ethidium bromide (see 
Experimental Procedures for the interpretation of intercalation assays). The 
positions of supercoiled (FI) and nicked circular (FII) molecules are indicated. 
Relative DNA cleavage of linear plasmid, or negatively or positively supercoiled 
molecules in the absence (-EtBr, open bars) or presence (+EtBr, closed bars) of 10 
µM eithdium bromide also is depicted (right panel). Relative DNA cleavage was 
calculated by normalizing levels of scission in the absence of ethidium bromide to 
a value of 1.0. Error bars represent the standard deviation of three independent 
assays for supercoiled substrates, or the standard error of the mean for two 
independent assays for linear DNA. 
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with linear pBR322. These results suggest that ethidium bromide inhibits DNA 
cleavage mediated by human topoisomerase IIα primarily by altering the 
apparent topology of the DNA substrate and to a lesser extent by accumulation 
within the double helix.  
 The second experiment examined the effects of a broad concentration range 
of amsacrine or TAS-103 on DNA scission mediated by topoisomerase IIα. In 
contrast to ethidium bromide, these two intercalating drugs are potent 
topoisomerase II poisons that enhance DNA cleavage (15,112,113). The initial 
study examined amsacrine. When negatively supercoiled plasmids were 
employed as the substrate, peak levels of cleavage were observed between 25 
and 50 µM drug (Figures 22 and 24, left panel). This is the amsacrine 
concentration range in which changes in DNA topology begin to appear (Figure 
24, left panel inset). Cleavage levels dropped ~50% between 25 and 250 µM drug 
and plateaued thereafter (Figure 24, left panel). It is notable that “full” 
intercalation is observed at an amsacrine concentration of ~200 µM (see inset). As 
discussed above, these findings are consistent with the suggestion that the rise in 
drug-induced DNA cleavage by amsacrine is attenuated by the concomitant fall 
in baseline scission caused, at least in part, by the apparent change in the 
geometry of the plasmid substrate. 
 A different pattern was seen with positively supercoiled substrates. Levels of 
DNA scission peaked between 100 and 200 µM amsacrine and remained constant 
at higher drug concentrations (Figure 24, left panel). Because of the changes in 
cleavage enhancement seen with negatively and positively supercoiled 
substrates, the superhelical specificity of amsacrine-induced DNA cleavage was 
concentration-dependent. Values were in the range of 1.0–1.5 at drug  
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Figure 24. Effects of amsacrine and TAS-103 intercalation on DNA cleavage 
mediated by human topoisomerase IIα. The ability of topoisomerase IIα to 
cleave negatively [(-)SC, open circles] or positively [(+)SC, closed circles] 
supercoiled pBR322 plasmid DNA in the presence of 0–500 µM amsacrine (left 
panel) or 0–200 µM TAS-103 (right panel) is shown. Error bars represent the 
standard deviation of three independent assays. The insets show representative 
DNA intercalation assays in the absence of topoisomerase IIα (-TII), or in the 
absence (0 µM) or presence of the respective drug (see Experimental Procedures 
for the interpretation of intercalation assays). The positions of supercoiled (FI) 
and nicked circular (FII) molecules are indicated.  
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concentrations that did not substantially alter the apparent topology of 
negatively supercoiled substrates (<25 µM), increased to 3.0–3.5 at concentrations 
that began to affect apparent topology (25–150 µM), and plateaued at ~5.1 at 
concentrations that induced full intercalation. It is notable that the plateau level 
of cleavage observed with positively supercoiled DNA was higher than that 
observed with negatively supercoiled molecules. It is unlikely that amsacrine 
intercalation could make negatively supercoiled plasmids appear to be more 
overwound than positively supercoiled molecules at a comparable drug 
concentration (see Figure 23). Therefore, it is concluded that the preferential 
accumulation of amsacrine in underwound substrates also contributes to the 
decrease in DNA cleavage observed with negatively supercoiled molecules at 
high drug concentrations.   
 To determine whether the concentration dependence of superhelical 
specificity is a general feature of intercalative drugs, the ability of TAS-103 to 
induce DNA cleavage by topoisomerase IIα was examined (Figure 24, right 
panel). Results were similar to those seen with amsacrine. Scission of negatively 
supercoiled plasmid rose initially, peaked at drug concentrations that began to 
alter the apparent topology of the substrate, and fell to approximately baseline 
thereafter. Conversely, scission of positively supercoiled plasmids increased and 
remained high over the entire range of TAS-103 examined (Figure 24, right panel). 
As a result, the superhelical specificity of TAS-103, like amsacrine, was 
concentration dependent. Values were 1.2–1.6 at drug concentrations that did not 
substantially alter the apparent topology of negatively supercoiled substrates (<5 
µM), increased to 2.6–3.7 at concentrations that begin to affect apparent topology 
(5–10 µM), and plateaued at 7.1–9.3 at concentrations that induced full 
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intercalation. This concentration dependence for superhelical specificity is in 
sharp contrast to those calculated for non-intercalative compounds and may be a 
defining distinction between intercalative and non-intercalative topoisomerase II 
poisons. 
 
Effects of DNA Supercoil Geometry on Drug-induced DNA Cleavage Mediated by 
Human Topoisomerase IIβ.  
 
 In contrast to human topoisomerase IIα, topoisomerase IIβ is not required for 
DNA replication and does not preferentially remove positive superhelical twists 
(13,34,38,42,44,65). However, the effects of nucleic acid geometry on DNA 
cleavage mediated by the β isoform have never been examined. Since 
topoisomerase IIβ is an important target for anticancer drugs (97) and also 
appears to mediate some of the toxic effects of these agents in differentiated 
tissues (95-97), the ability of the enzyme to cleave positively vs. negatively 
supercoiled substrates in the presence of topoisomerase II-targeted drugs was 
assessed.  
  Similar to topoisomerase IIα, topoisomerase IIβ maintains lower (~3– to 4–
fold) levels of cleavage complexes with positively supercoiled DNA in the 
absence of drug (Figures 18 and 25). The enzyme also displayed lower (~2–fold) 
cleavage activity with positively supercoiled substrates over a range of etoposide 
concentrations (Figure 25). However, the effects of DNA geometry on drug-
induced scission were not as pronounced with topoisomerase IIβ as they were 
with the α isoform. As seen in Figure 26, the percentage of positively supercoiled 
molecules cleaved in the presence of several drugs approached or actually 
exceeded that observed with negatively supercoiled substrates. Consequently,  
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Figure 25. Human topoisomerase IIβ maintains lower levels of DNA cleavage 
complexes with positively supercoiled plasmids in the presence of etoposide. 
The ability of topoisomerase IIβ to cleave negatively [(-)SC, open circles] or 
positively [(+)SC, closed circles] supercoiled pBR322 plasmid DNA in the 
presence of 0–100 µM etoposide is shown. Error bars represent the standard 
deviation of three independent assays. The inset shows a representative ethidium 
bromide-stained agarose gel of DNA cleavage assays with negatively and 
positively supercoiled plasmids in the absence of topoisomerase IIβ (-TII) and in 
the absence (no drug, ND) or presence (Etop) of etoposide. Linear DNA standards 
(Lin) also are shown. The positions of supercoiled (FI), nicked circular (FII), and 
linear molecules (FIII) are indicated.  
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Figure 26. Effects of DNA superhelical geometry on drug-induced DNA 
cleavage mediated by human topoisomerase IIβ. The ability of topoisomerase IIβ 
to cleave negatively [(-)SC DNA, open bars] or positively [(+)SC DNA, closed 
bars] supercoiled pBR322 plasmid DNA in the presence of various topoisomerase 
II-targeted drugs is shown. All drugs were used at a concentration of 50 µM, 
except for CP-115,953, which was used at 5 µM (multiple DNA cleavage events 
per plasmid were observed at higher concentrations of CP-115,953). Error bars 
represent the standard deviation of 3 or 4 independent assays. 
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the calculated superhelical specificities for most drugs were somewhat higher for 
topoisomerase IIβ than they were for topoisomerase IIα (Table 2). Once again, the 
superhelical specificity of the non-intercalative compounds was concentration-
independent and remained constant at all drug concentrations examined. 
Furthermore, the highest superhelical specificities were observed for the two 
intercalative drugs, TAS-103 and amsacrine.  
 To further analyze this finding, the effects of amsacrine and TAS-103 on 
DNA scission mediated by topoisomerase IIβ were examined over a broad 
concentration range (data not shown). As found with the α isoform, levels of 
negatively supercoiled DNA cleaved by topoisomerase IIβ peaked at drug 
concentrations at which changes in apparent topology were obvious, dropped, 
and plateaued at concentrations that induced full intercalation. In contrast, levels 
of cleavage with positively supercoiled substrates increased and remained high 
over the entire drug ranges examined. Thus, as discussed above for 
topoisomerase IIα, the superhelical specificities for amsacrine and TAS-103 were 
concentration-dependent with topoisomerase IIβ, and rose from initial values of 
1.2 and 1.7, respectively, at low concentrations, to 8.3 and 9.1, respectively, at 
high concentrations. These results further suggest that drug-induced cleavage of 
underwound substrates by topoisomerase IIβ is attenuated by the ability of 
intercalative agents to change the apparent geometry of DNA and by increased 
drug accumulation on negatively supercoiled molecules. 
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Table 2. Relative DNA cleavage enhancement of human topoisomerase IIβ by 
anticancer agents. 
 
Druga Relative Cleavage 
Enhancement  
(-)SC DNA 
Relative Cleavage 
Enhancement 
(+)SC DNA 
Superhelical 
Specificity 
[(+)SC/(-)SC] 
Etoposide 4.9 ± 0.3 8.2 ± 0.5 1.6 
TOP-53 7.9 ± 0.6 20.9 ± 0.9 2.7 
Genistein 8.5 ± 0.2 22.0 ± 2.1 2.6 
CP-115,953 5.6 ± 1.8 10.4 ± 4.8 1.9 
TAS-103 1.7 ± 0.3 12.6 ± 1.3 7.3 
Amsacrine 7.8 ± 1.1 31.7 ± 4.7 4.1 
 
 aAll drugs were at 50 µM, with the exception of CP-115-953, which was at 5 
µM (multiple DNA cleavage events per plasmid were observed at higher 
concentrations of CP-115,953). 
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Effects of DNA Supercoil Geometry on Drug-induced DNA Cleavage Mediated by 
Human Topoisomerase I.  
 
 Topoisomerase I is an important target for several new anticancer drugs that 
are based on camptothecin, a naturally occurring non-intercalative compound 
found in the bark of the Chinese tree Camptotheca acuminata (17,19,26-28). These 
drugs kill cells by increasing levels of single-stranded DNA breaks (i.e., nicks) 
that are generated by the type I enzyme (17,19,89). Since one of the major 
functions of topoisomerase I is to alleviate torsional stress that builds up ahead of 
replication forks and transcription complexes (13,14,19), the effects of nucleic 
acid geometry on enzyme-mediated DNA cleavage was examined in the absence 
or presence of camptothecin (Figure 27). 
 In sharp contrast to the type II enzymes, human topoisomerase I maintained 
a higher level of cleavage intermediates with overwound DNA. Three times 
more nicked molecules were generated with positively supercoiled plasmids 
than were observed with negatively supercoiled substrates (see bar graph inset). 
A far more striking effect of DNA geometry on topoisomerase I was seen in the 
presence of camptothecin (Figure 27). Over a concentration range of 1–25 µM 
drug, the enzyme generated dramatically higher levels of nicked DNA with 
positively supercoiled substrates. For example, at 1 µM camptothecin, ~16 times 
more DNA cleavage was observed with positively as compared to negatively 
supercoiled pBR322, yielding a superhelical specificity of 4.7. Together with the 
findings for the type II enzymes, these results demonstrate that the handedness 
of DNA supercoils has a profound influence on DNA cleavage reactions 
mediated by human topoisomerases. 
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Figure 27. Human topoisomerase I maintains higher levels of DNA cleavage 
complexes with positively supercoiled plasmids in the absence or presence of 
camptothecin. The ability of topoisomerase I to cleave negatively [(-)SC, open 
circles] or positively [(+)SC, closed circles] supercoiled pBR322 plasmid DNA in 
the presence of 0–25 µM campthothecin is shown. Error bars represent the 
standard deviation of three independent assays. The inset shows a representative 
ethidium bromide-stained agarose gel of DNA cleavage assays with negatively 
and positively supercoiled plasmids in the absence of topoisomerase I (-TI) and in 
the absence (no drug, ND) or presence (Cpt) of 5 µM camptothecin. Linear DNA 
standards (Lin) also are shown. The positions of supercoiled (FI), nicked circular 
(FII), and linear molecules (FIII) are indicated. The inset also shows a bar graph 
highlighting topoisomerase I-mediated DNA cleavage of negatively (open bar) 
and positively (closed bar) supercoiled DNA in the absence of drug. 
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Discussion 
 
 Beyond their critical physiological functions, topoisomerases are targets for a 
number of important anticancer drugs (15-19,91-94). While these agents all 
increase the concentration of topoisomerase-generated breaks in the genetic 
material (15,16,19,89,90), their ability to kill cells requires the actions of DNA 
tracking systems, such as replication or transcription complexes (15,16,19,89,90). 
Collisions between tracking systems and cleavage complexes convert these 
transient enzyme intermediates to permanent DNA strand breaks either directly, 
or by the induction of recombination (15,16,76-78). It is the accumulation of these 
permanent strand breaks that ultimately triggers cell death pathways (77). 
 Previous studies on the interaction of anticancer drugs and topoisomerases 
have used negatively supercoiled or linear DNA as cleavage substrates. 
However, the movement of enzymes through the double helix leads to the 
formation of overwound DNA ahead of tracking systems (3,5-7,11,238-240). As a 
result, the cleavage complexes most likely to produce permanent DNA strand 
breaks should form between topoisomerases and positively supercoiled DNA. 
Therefore, the ability of human topoisomerase IIα and β, and topoisomerase I to 
cleave positively supercoiled molecules was assessed in the absence or presence 
of anticancer drugs. 
 As discussed in chapter III of this dissertation, topoisomerase IIα and β both 
maintain ~3– to 4–fold lower levels of cleavage complexes with positively 
supercoiled DNA than with negatively supercoiled molecules. This decrease in 
nucleic acid scission may benefit the cell, because it makes it less likely that the 
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actions of a DNA tracking system will generate permanent topoisomerase II-
associated strand breaks during normal cellular processes.  
 Topoisomerase IIα also maintains lower concentrations of drug-induced 
cleavage intermediates with positively supercoiled substrates. With the non-
intercalative agents examined, the relative enhancement of DNA scission seen 
with overwound DNA is similar to that observed with underwound molecules. 
Furthermore, the superhelical specificity for DNA cleavage appears to be 
independent of drug concentration. Consequently, it is proposed that decreased 
drug efficacy is due primarily to a drop in baseline levels of cleavage mediated 
by topoisomerase IIα, rather than an altered interaction with the enzyme-DNA 
complex.  
 Results were somewhat different for topoisomerase IIβ. Whereas some non-
intercalative drugs such as etoposide and CP-115,953, follow trends similar to 
those seen for the α isoform, others, such as genistein and TOP-53, induced 
equivalent levels of cleavage with positively and negatively supercoiled 
plasmids. The underlying reason for the increased drug effect with positively 
supercoiled DNA is not known. However, this finding suggests that in some 
cases, drug-induced stimulation of DNA cleavage by topoisomerase IIβ is more 
likely to generate permanent strand breaks than would topoisomerase IIα under 
comparable circumstances. This difference notwithstanding, the superhelical 
specificity for DNA cleavage with non-intercalative drugs was once again 
concentration-independent. 
 Consistently, with both topoisomerase IIα and β, intercalative drugs 
displayed higher relative cleavage enhancement in the presence of positively 
rather than negatively supercoiled DNA. This superhelical specificity did not 
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correlate with a greater intrinsic drug activity with overwound substrates. 
Rather, it appears to result from the apparent positive supercoiling of 
underwound molecules and the preferential accumulation of intercalative drugs 
in negatively supercoiled substrates. At higher drug concentrations, these effects 
attenuate the stimulation of topoisomerase II-mediated DNA cleavage of 
negatively supercoiled molecules and result in an increased superhelical 
specificity. As a result, they probably are responsible for the characteristic “bell-
shaped curve” observed for the enhancement of scission by intercalative 
anticancer drugs. In contrast, DNA cleavage by topoisomerase II rises and 
plateaus with positively supercoiled substrates. This finding implies that 
intercalative agents are able to maintain their effectiveness ahead of DNA 
tracking systems, even at high drug concentrations. 
 Results with topoisomerase I were unexpected. Despite the fact that this 
enzyme characteristically functions to alleviate overwinding ahead of DNA 
tracking systems (14,17,19), it maintains ~3 times higher levels of cleavage 
complexes with positively supercoiled substrates. Thus, under normal 
physiological circumstances, topoisomerase I is inherently more likely to trigger 
the formation of permanent DNA strand breaks than either type II isoform. The 
cellular ramifications of this enzyme feature are unclear at the present time.  
 The influence of DNA topology on topoisomerase I-mediated scission is 
even more dramatic in the presence of camptothecin. This finding suggests that 
topoisomerase I may be an intrinsically more lethal target for anticancer drugs 
than is topoisomerase IIα or β. 
 In summary, numerous factors influence the effectiveness of topoisomerase-
targeted anticancer drugs, including the concentration, localization, and roles 
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played by each enzyme in specific nucleic acid processes. Results of the present 
study indicate that the topological state of the genetic material also has a 
profound influence on topoisomerase-mediated DNA cleavage and the response 
of topoisomerase IIα, topoisomerase IIβ, and topoisomerase I to anticancer drugs. 
Although topoisomerase IIα is the enzyme that is most frequently targeted by 
chemotherapeutic regimens, it may actually be the topoisomerase that is least 
likely to generate cleavage complexes that are converted to permanent DNA 
strand breaks in treated cells. Alternatively, all other things being equal, 
topoisomerase I appears to be the enzyme most likely to fragment the genome. 
This may be one of the reasons why camptothecin-based drugs display a 
spectrum of activity that exceeds those of other established anticancer agents. 
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CHAPTER V 
 
BIOMODAL RECOGNITION OF DNA SUPERCOIL GEOMETRY BY TYPE II 
TOPOISOMERASES 
 
 
Introduction 
  Recently, it was demonstrated that some type II enzymes are capable of 
discerning the geometry of DNA supercoils. Human topoisomerase IIα (chapter 
III, Figure 12) and E. coli topoisomerase IV (213,214) both relax positive 
superhelical twists more than an order of magnitude faster than they do negative 
superhelical twists. In contrast, yeast and Drosophila topoisomerase II (chapter III, 
Figure 19), and human topoisomerase IIβ (chapter III, Figure 14) relax negatively 
and positively supercoiled plasmids at similar rates (217). Although type II 
topoisomerases possess a high degree of amino acid sequence identity in their N-
terminal and central homology domains (GyrB and GyrA domains, respectively), 
these enzymes diverge considerably in their C-terminal domains 
(14,15,18,243,244). Based on these amino acid sequence differences, it was 
suggested in chapter III of this dissertation that the ability of human 
topoisomerase IIα to preferentially relax positive DNA supercoils resides in the 
C-terminal domain of the protein. Structural and modeling studies of 
topoisomerase IV and DNA gyrase, coupled with nucleic acid binding 
experiments, have led to similar conclusions for the bacterial type II enzymes (62-
64).  
 In addition to their ability to distinguish supercoil geometry during DNA 
relaxation, type II topoisomerases also discern the handedness of supercoils 
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during the DNA cleavage event (chapter III, Figures 17 and 18). Both 
topoisomerase IIα and β maintain lower levels (3– to 4–fold) of cleavage 
intermediates when positively supercoiled substrates are employed. Because the 
human isoforms display different results in DNA relaxation and cleavage assays, 
the type II enzyme must utilize distinct mechanisms to distinguish DNA 
geometry during these two processes.  
 To more fully assess the recognition of DNA geometry by type II 
topoisomerases, two groups of enzymes were studied (Figure 28 and 29). The 
first group consisted of type II topoisomerases that lack the C-terminal protein 
domain. Two of these enzymes are encoded by Paramecium bursaria chlorella 
virus-1 (PBCV-1) and chlorella virus Marburg-1 (CVM-1) (201-204). They are 
homologous to human topoisomerase IIα, but naturally lack the C-terminal 
domain (Figure 28). Chlorella virus type II topoisomerases display high levels of 
DNA cleavage, but in other respects are similar to eukaryotic topoisomerase II. 
The third enzyme in this group, hTop2αΔ1175, is a deletion mutant of human 
topoisomerase IIα that is truncated at the amino acid residue that corresponds to 
the C-terminus of PBCV-1 topoisomerase II (Figure 28) (205). These three 
truncated enzymes allow for the examination of the recognition of DNA 
supercoil geometry in the absence of the variable C-terminal domain, which is 
thought to be involved in modulating DNA relaxation by topoisomerase II. 
 The second group of enzymes studied consists of two additional mutant 
enzymes of human topoisomerase IIα in which the C-terminal domains have 
been switched (Figure 29). Results indicate that topoisomerase II uses elements in 
the conserved N-terminal or central domains to recognize supercoil geometry  
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Figure 28. Domain structures of type II topoisomerases lacking the C-terminal 
variable region. The domain structures of human topoisomerase IIα, PBCV-1 
topoisomerase II, CVM-1 topoisomerase II and a C-terminal truncation mutant of 
human topoisomerase IIα (hTop2αΔ1175) are shown. The human and viral type 
II enzymes contain similar ATPase (blue) and cleavage/religation domains 
(pink). The active site tyrosine residues (human: Y805, PBCV-1: Y743, CVM-1: 
Y737) are indicated. PBCV-1 and CVM-1 topoisomerase II are naturally lacking 
the variable C-terminal domain of type II topoisomerases (yellow), and human 
topoisomerase IIαΔ1175 has been truncated at amino acid 1175 (the residue 
corresponding to the terminal residue of PBCV-1 topoisomerase II). 
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Figure 29. Domain structures of human topoisomerase IIαCTDβ and 
topoisomerase IIβCTDα. The domain structures of human topoisomerase 
IIαCTDβ and topoisomerase IIβCTDα are shown. The ATPase (blue) and 
cleavage/religation domains (pink) of the human isoforms are ~79% 
homologous. The variable C-terminal domain (yellow) is only ~31% 
homologous. The active site tyrosine residues (topoisomerase IIα: Y805, 
topoisomerase IIβ: Y821) are indicated, as well as the amino acid length of each 
mutant (hTop2αCTDβ: 1621 amino acids, hTop2βCTDα: 1531 amino acids). 
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during DNA cleavage and elements in the C-terminal domain to sense the 
handedness of supercoils during DNA relaxation. 
 
Results 
 
Relaxation of Negatively and Positively Supercoiled DNA by Chlorella Virus Type II 
Topoisomerases 
 
 It was proposed in chapter III of this dissertation that the C-terminal domain 
of topoisomerase IIα plays an important role in sensing DNA geometry during 
relaxation. As an initial test of this hypothesis, the ability of two viral enzymes, 
PBCV-1 and CVM-1 topoisomerase II, that naturally lack the C-terminal domain 
to relax negatively and positively supercoiled DNA was examined. Results of 
DNA relaxation assays are shown in Figures 30 (PBCV-1) and 31 (CVM-1). Both 
viral enzymes displayed high rates of DNA relaxation irrespective of the 
handedness of the initial plasmid substrates. As determined by two methods of 
quantitation (percent DNA relaxation from the gain of relaxed product or the 
loss of supercoiled substrate), PBCV-1 and CVM-1 topoisomerase II relaxed 
negatively and positively supercoiled DNA at similar rates. These findings 
support the hypothesis that the C-terminal domain of the protein is required for 
topoisomerase II to sense the handedness of DNA during relaxation. 
 
Cleavage of Negatively and Positively Supercoiled DNA by Chlorella Virus Type II 
Topoisomerases 
 
 As a prerequisite to the strand passage event, topoisomerase II generates a 
transient double-stranded break in the genetic material (14-16,18,30). In contrast  
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Figure 30. PBCV-1 topoisomerase II relaxes negatively and positively 
supercoiled plasmid DNA at similar rates. Ethidium bromide-stained gels (top) 
depict a time course for relaxation of negatively [(-)SC, left gel] or positively 
[(+)SC, right gel] supercoiled pBR322 plasmid DNA by PBCV-1 topoisomerase II. 
The positions of the supercoiled DNA (form I, FI) and relaxed DNA (form II, FII) 
are indicated. DNA relaxation was quantified from either the gain of relaxed 
product (left panel) or the loss of supercoiled substrate (right panel). Data for 
negatively supercoiled substrates are represented by open symbols and positively 
supercoiled substrates by closed symbols. Error bars represent the standard 
deviation of three independent experiments. This data was generated by Dr. 
Jennifer Dickey. 
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Figure 31. CVM-1 topoisomerase II relaxes negatively and positively 
supercoiled plasmid DNA at similar rates. Ethidium bromide-stained gels (top) 
depict a time course for relaxation of negatively [(-)SC, left gel] or positively 
[(+)SC, right gel] supercoiled pBR322 plasmid DNA by CVM-1 topoisomerase II. 
The positions of the supercoiled DNA (form I, FI) and relaxed DNA (form II, FII) 
are indicated. DNA relaxation was quantified from either the gain of relaxed 
product (left panel) or the loss of supercoiled substrate (right panel). Data for 
negatively supercoiled substrates are represented by open symbols and positively 
supercoiled substrates by closed symbols. Error bars represent the standard 
deviation of three independent experiments. This data was generated by Dr. 
Jennifer Dickey. 
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to results observed for DNA relaxation, both human topoisomerase IIα and β are 
able to discern the handedness of supercoils during the DNA cleavage event 
(chapter III, Figures 17 and 18). This finding demonstrates that topoisomerase II 
employs distinct mechanisms to recognize DNA geometry during different 
catalytic processes and suggests that the ability to distinguish the handedness of 
supercoils during the cleavage event resides in the conserved N-terminal or 
central domains of the enzyme. To address this issue, the effects of DNA under- 
and overwinding on the cleavage activities of PBCV-1 and CVM-1 topoisomerase 
II were examined (Figure 32). 
 Both viral enzymes were able to discern supercoil geometry during the DNA 
cleavage reaction. As found for the human enzymes, levels of DNA cleavage 
intermediates generated by PBCV-1 and CVM-1 topoisomerase II were ~2– to 4–
fold lower when positively supercoiled plasmids were used as substrates (Figure 
32). These results provide strong evidence that the elements that sense the 
handedness of DNA supercoils during the cleavage reaction of topoisomerase II 
must reside in the conserved N-terminal or central domain of the protein, rather 
than the C-terminal domain.  
 Three additional experiments were carried out to further investigate the 
recognition of DNA geometry during the cleavage event. First, the effects of 
DNA handedness on the site specificity of PBCV-1 and CVM-1 topoisomerase II 
were examined (Figure 33). Each enzyme cut negatively and positively 
supercoiled substrates at the same sites. However, levels of scission were 
reduced at all sites in the overwound molecules. Thus, the decrease in cleavage 
observed with positively supercoiled DNA does not result from a geometry-
specific alteration in site specificity.  
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Figure 32. Type II topoisomerases from chlorella viruses maintain lower levels 
of DNA cleavage complexes with positively supercoiled DNA than with 
negatively supercoiled molecules. The ability of 0-40 nM PBCV-1 (left panel) or 
CVM-1 (right panel) topoisomerase II to cleave 10 nM negatively [(-)SC, open 
symbols] or positively [(+)SC, closed symbols] supercoiled pBR322 plasmid DNA 
is shown. Error bars represent the standard deviation of three independent 
experiments. This data was generated by Dr. Jennifer Dickey. 
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Topo II:    -    +    -   +         -   +    -   + 
 (-)SC  (+)SC (-)SC   (+)SC 
PBCV-1 CVM-1 
Figure 33. The DNA cleavage specificity of chlorella virus type II 
topoisomerases is not altered by the handedness of the supercoiled substrate. 
Sites cleaved by PBCV-1 or CVM-1 topoisomerase II were mapped in negatively 
[(-)SC] or positively [(+)SC] supercoiled pBR322 plasmid DNA. Products of DNA 
cleavage assays were linearized and singly-end labeled with [32P]phosphate. The 
autoradiogram is representative of at least two independent assays. 
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 Second, the effects of supercoil geometry on enzyme-DNA binding were 
characterized (Figure 34). As determined by competition binding experiments, 
PBCV-1 and CVM-1 topoisomerase II bound negatively and positively 
supercoiled plasmids with similar affinity. Therefore, the recognition of DNA 
handedness during cleavage does not reflect an increased affinity for negatively 
supercoiled substrates. 
 Third, the effects of supercoil handedness on enzyme-mediated DNA 
religation were examined (Figure 35). Similar rates of religation were observed 
for both viral enzymes with negatively and positively supercoiled substrates. 
Taken together, these results suggest that the effects of supercoil geometry must 
manifest themselves somewhere between the initial DNA binding and religation 
events. Most likely, the actual cleavage event is impacted by the handedness of 
the DNA substrate. 
 
Relaxation and Cleavage of Negatively and Positively Supercoiled DNA by Human 
Topoisomerase IIαΔ1175 
 
 To further assess the potential role of the C-terminal domain of human 
topoisomerase IIα as a sensor of DNA geometry during relaxation and cleavage, 
and to confirm the results generated with the viral type II enzymes, a C-terminal 
deletion mutant of human topoisomerase IIα (hTop2αΔ1175) was generated.  
hTop2αΔ1175 allows a direct comparison between full length human 
topoisomerase IIα and an equivalent enzyme that contains only its ATPase and 
cleavage/ligation domains. Thus, the ability of hTop2αΔ1175 to relax and cleave 
negatively and positively supercoiled DNA was characterized. As seen in Figure 
36, rates of DNA relaxation for negatively and positively supercoiled plasmids  
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Figure 34. Type II topoisomerases from chlorella viruses display similar 
binding affinities for negatively and positively supercoiled DNA. The ability of 
0–20 nM negatively supercoiled [(-)SC, open symbols] or positively [(+)SC, closed 
symbols] supercoiled pBR322 plasmid DNA to compete with the binding of 5 nM 
[32P]-labeled linear pBR322 DNA by PBCV-1 (left panel) or CVM-1 (right panel) 
topoisomerase II is shown. Percent linear DNA bound was determined by the 
ratio of cpm retained on a nitrocellulose filter vs. the input amount of 
radioactivity. Error bars represent the standard deviation of three independent 
assays. 
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Figure 35. Type II topoisomerases from chlorella viruses display similar rates 
of religation with negatively and positively supercoiled DNA. A time course of 
religation in the presence of negatively [(-)SC, open symbols] or positively [(+)SC, 
closed symbols] supercoiled pBR322 plasmid by PBCV-1 (left panel) or CVM-1 
(right panel) is shown. The initial level of DNA cleavage was set to 100% and the 
rate of ligation was determined by quantifying the loss of the cleaved DNA over 
time. Error bars represent the standard deviation of three independent assays. 
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Figure 36. Human topoisomerase IIαΔ1175 does not preferentially relax 
positively supercoiled DNA. Ethidium bromide-stained agarose gels displaying 
representative time courses for relaxation of negatively supercoiled [(-) SC; left 
gel] or positively supercoiled  [(+) SC; right gel] pBR322 plasmid DNA by human 
topoisomerase IIαΔ1175 are shown. The positions of supercoiled DNA (form I, FI) 
and relaxed DNA (form II, FII) are indicated. DNA relaxation was quantified 
from either the gain of fully relaxed product (left panel) or the loss of supercoiled 
substrate (right panel). Error bars represent the standard deviation at least three 
independent assays. 
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were equivalent with hTop2αΔ1175. Therefore, removal of the C-terminal 
domain of the human enzyme abrogated the ability of topoisomerase IIα to sense 
supercoil geometry during DNA relaxation. 
  In contrast, removal of the C-terminal domain of topoisomerase IIα did not 
affect the ability of the enzyme to recognize DNA geometry during the cleavage 
reaction. As seen in Figure 37, hTop2αΔ1175 maintained lower (~3-fold) levels of 
cleavage complexes with positively rather than negatively supercoiled 
substrates.  Additionally, as observed with the chlorella virus type II enzymes, 
hTop2αΔ1175 displayed similar binding affinities (Figure 38) and religation rates 
(Figure 39) with negatively and positively supercoiled plasmids. Therefore, the 
recognition of DNA handedness during cleavage does not reflect an increased 
affinity for negatively supercoiled DNA or faster rates of religation with these 
substrates. 
 Taken together, the results obtained with PBCV-1 topoisomerase II, CVM-1 
topoisomerase II, and hTop2αΔ1175 suggest that the elements of the protein that 
sense the handedness of supercoils during DNA relaxation must reside in the 
variable C-terminal domain of topoisomerase II. In contrast, the elements that 
sense the handedness of supercoils during DNA cleavage must be located in 
conserved N-terminal or central domain of the enzyme. 
 
Relaxation of Negatively and Positively Supercoiled DNA by Human Topoisomerase 
IIαCTDβ and Topoisomerase IIβCTDα. 
 
 Results obtained with type II topoisomerases that lack the C-terminal 
domain suggest that this portion of the enzyme contains residues for facilitating 
the recognition and preferential relaxation of positively supercoiled DNA. 
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Figure 37. Human topoisomerase IIαΔ1175 maintains lower levels of DNA 
cleavage complexes with positively supercoiled DNA than with negatively 
supercoiled molecules. The ability of 0-800 nM hTop2αΔ1175 to cleave 10 nM 
negatively [(-)SC, open symbols] or positively [(+)SC, closed symbols] supercoiled 
pBR322 plasmid DNA is shown. Error bars represent the standard deviation of 
three independent experiments. 
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Figure 38. Human topoisomerase IIαΔ1175 displays similar binding affinities 
for negatively and positively supercoiled DNA. The ability of 0–20 nM 
negatively supercoiled [(-)SC, open symbols] or positively [(+)SC, closed symbols] 
supercoiled pBR322 plasmid DNA to compete with the binding of 5 nM [32P]-
labeled linear pBR322 DNA by hTop2αΔ1175 is shown. Percent linear DNA 
bound was determined by the ratio of cpm retained on a nitrocellulose filter vs. 
the input amount of radioactivity. Error bars represent the standard deviation of 
three independent assays. 
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Figure 39. Human topoisomerase IIαΔ1175 displays similar rates of religation 
with negatively and positively supercoiled DNA. A time course of religation in 
the presence of negatively [(-)SC, open symbols] or positively [(+)SC, closed 
symbols] supercoiled pBR322 plasmid by hTop2αΔ1175 is shown. The initial level 
of DNA cleavage was set to 100% and the rate of ligation was determined by 
quantifying the loss of the cleaved DNA over time. Error bars represent the 
standard deviation of three independent assays. 
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However, it is possible that the C-terminal domain does not interact directly with 
the DNA substrate. Instead, its presence may alter the structure of topoisomerase 
II and allow other regions of the enzyme to recognize DNA topology. Therefore, 
to more fully examine the role of the C-terminal domain of human 
topoisomerase IIα in the recognition of supercoil geometry during DNA 
relaxation, two additional mutants enzymes were generated in which the C-
terminal domains of human topoisomerase IIα and β were switched (Figure 29). 
 The ability of human topoisomerase IIα that carries the C-terminal domain of 
topoisomerase IIβ (hTop2αCTDβ) and topoisomerase IIβ that carries the C-
terminal domain of topoisomerase IIα (hTop2βCTDα) to relax negatively and 
positively supercoiled DNA was examined. While topoisomerase IIα displays 
preferential relaxation of positively supercoiled DNA, addition of the C-terminal 
domain of topoisomerase IIβ results in an enzyme that no longer recognizes 
supercoil geometry during relaxation. As seen in Figure 40, hTop2αCTDβ relaxed 
negatively and positively supercoiled substrates with similar rates. Furthermore, 
topoisomerase IIβ, which does not preferentially relax positively supercoiled 
DNA, gained this characteristic with the addition the C-terminal domain of 
topoisomerase IIα. As seen in Figure 41, hTop2βCTDα relaxes positively 
supercoiled substrates >10-fold faster than negatively supercoiled molecules. 
These results strongly support the hypothesis that the recognition and rapid 
relaxation of positively supercoiled DNA by human topoisomerase IIα is 
modulated by the C-terminal domain of the enzyme. 
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Figure 40. Human topoisomerase IIαCTDβ displays similar relaxation rates 
with negatively and positively supercoiled DNA. Ethidium bromide-stained 
agarose gels displaying representative time courses for relaxation of negatively 
supercoiled [(-) SC; left gel] or positively supercoiled  [(+) SC; right gel] pBR322 
plasmid DNA by human topoisomerase IIαCTDβ are shown. The positions of 
supercoiled DNA (form I, FI) and relaxed DNA (form II, FII) are indicated. DNA 
relaxation was quantified from either the gain of fully relaxed product (left panel) 
or the loss of supercoiled substrate (right panel). Error bars represent the standard 
deviation at least three independent assays. 
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Figure 41. Human topoisomerase IIβCTDα  relaxes positively supercoiled DNA 
faster than negatively supercoiled DNA. Ethidium bromide-stained agarose gels 
displaying representative time courses for relaxation of negatively supercoiled [(-) 
SC; left gel] or positively supercoiled  [(+) SC; right gel] pBR322 plasmid DNA by 
human topoisomerase IIβCTDα are shown. The positions of supercoiled DNA 
(form I, FI) and relaxed DNA (form II, FII) are indicated. DNA relaxation was 
quantified from either the gain of fully relaxed product (left panel) or the loss of 
supercoiled substrate (right panel). Error bars represent the standard deviation at 
least three independent assays. 
 
 110 
Discussion 
 
Bimodal Recognition of DNA Supercoil Geometry by Topoisomerase II 
 Previous studies with human and bacterial topoisomerases (62-64,213,214) 
suggest that the type II enzyme utilizes two distinct mechanisms to recognize the 
handedness of DNA supercoils. It has been proposed that the ability of some 
type II enzymes, such as human topoisomerase IIα and E. coli topoisomerase IV, 
to distinguish supercoil geometry during DNA relaxation is mediated by 
elements in the variable C-terminal domain (62-64). In contrast, the ability of 
human topoisomerase IIα and β to discern the handedness of DNA during 
cleavage suggests that residues in the conserved N-terminal or central domain of 
the protein are involved in this process.  
 As a first test of this hypothesis, the ability of three enzymes that lack the C-
terminal domain, PBCV-1 topoisomerase II, CVM-1 topoisomerase II (201,204), 
and hTop2αΔ1175, a C-terminal truncation mutant of human topoisomerase IIα, 
to relax and cleave negatively and positively supercoiled plasmids was 
compared. While these enzymes relaxed under- and overwound substrates at 
similar rates, they were able to discern the handedness of supercoils during the 
cleavage reaction and preferentially cut negatively supercoiled DNA. 
Preferential cleavage was not due to a change in site specificity, DNA binding, or 
DNA religation. These findings are consistent with a role for the C-terminal 
domain of topoisomerase II in sensing the geometry of superhelical twists during 
relaxation. Furthermore, they demonstrate that the intrinsic ability to discern 
supercoil geometry during DNA cleavage must reside within the conserved N-
terminal or central domain of the type II enzyme. 
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 To determine whether the recognition of supercoil geometry during DNA 
relaxation is actually carried within the C-terminal domain of human 
topoisomerase IIα, two additional mutants, hTop2αCTDβ and hTop2βCTDα 
were generated. While topoisomerase IIα displayed preferential relaxation of 
positively supercoiled DNA, hTop2αCTDβ no longer displays this preferential 
relaxation.  Additionally, while topoisomerase IIβ did not preferentially relax 
positively supercoiled DNA, hTop2βCTDα gained this characteristic. These 
results provide strong evidence that the C-terminal domain of topoisomerase IIα 
modulates the recognition and rapid relaxation of positively supercoiled 
substrates. 
 It is not clear how topoisomerase II utilizes elements in different protein 
domains to sense DNA geometry during different catalytic processes. However, 
based on our studies with human and chlorella virus type II topoisomerases, as 
well as models described for geometry sensing in bacterial topoisomerase IV (62-
64), we propose the following models for the actions of eukaryotic topoisomerase 
II.  
 
Recognition of DNA Supercoil Geometry by the N-terminal or Central Domain of 
Topoisomerase II 
 
 The conserved N-terminal or central domain of the eukaryotic enzyme 
possesses an intrinsic ability to sense the geometry of its DNA substrate. This 
postulate is supported by the fact that type II topoisomerases that lack the C-
terminal domain are still able to differentiate between under- and overwound 
substrates during DNA cleavage. The elements in the conserved domains of 
topoisomerase II that discern DNA geometry during cleavage are likely to be 
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located within (or proximal to) the active site of the protein. Two segments of 
DNA, the T- and G-segments, intersect as a crossover in the active site, 
irrespective of the supercoiled state of the nucleic acid substrate. However, the 
geometry of the crossover formed by negative or positive supercoils differs 
significantly. While DNA nodes formed with positively supercoiled molecules 
are left-handed and have acute angles (~60°), those formed with negatively 
supercoiled molecules are right-handed and have obtuse angles (~120°) (64,65). 
Therefore, elements in the conserved domains to topoisomerase II may be in 
direct contact with both the T- and the G-segments and provide the catalytic core 
of the enzyme with an innate ability to recognize the angle of the DNA crossover. 
Since the presence of the T-segment has been shown to increase scission of the G-
segment (245), it is possible that the geometry of the crossover may also affect the 
ability of topoisomerase II to generate breaks in the DNA backbone.  
 Alternatively, changes in DNA twist associated with under- and 
overwinding profoundly alter the properties of the double helix. Since the 
catalytic core of topoisomerase II is in intimate contact with the G-segment (30), 
the enzyme may recognize the twist of the G-segment rather than the angle of the 
DNA crossover and maintain lower levels of cleavage complexes with 
overwound substrates. 
 It should be noted that although elements in the conserved N-terminal or 
central domain of topoisomerase II can distinguish negative and positive 
superhelical twists, they promote strand passage of substrates containing either 
without prejudice. This is evidenced by the finding that enzymes that lack their 
C-terminal domains relax under- and overwound plasmids at similar rates.  
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Recognition of DNA Supercoil Geometry by the C-terminal Domain of Topoisomerase II 
 Although the C-terminal domain of the type II enzyme is distal to the active 
site of the protein, it is believed to have specific interactions with the T-segment 
during relaxation (62-64). In the case of positively supercoiled DNA, interactions 
with the C-terminal domain facilitate the strand passage reaction, resulting in 
faster rates of DNA relaxation. This point is supported by the fact that full-length 
human topoisomerase IIα and hTop2βCTDα preferentially relax overwound 
DNA.  Thus, recognition of DNA geometry during relaxation most likely is 
related to the path of the T-segment into and out of the active site of the enzyme 
that is imposed by handedness of the DNA crossover.  
 
Physiological Implications for the Bimodal Recognition of DNA Supercoil Geometry by 
Type II Topoisomerases 
 
 The variable C-terminal domain of bacterial type II topoisomerases appears 
to play important roles in determining the specific functions catalyzed by 
individual enzymes. For example, this region of the protein allows DNA gyrase 
to introduce negative supercoils into the bacterial chromosome (246,247) and 
topoisomerase IV to preferentially remove positive supercoils (213,214). Results 
of the present study suggest that the C-terminal domain may also endow specific 
eukaryotic type II topoisomerases with unique catalytic properties. For example, 
by using the variable C-terminal domain to distinguish positive from negative 
supercoils during relaxation, specific type II topoisomerases, such as human 
topoisomerase IIα, are better suited to actively participate in the removal of 
torsional stress ahead of replication forks or transcription complexes.  
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 In contrast, by using the conserved portions of the protein to discern DNA 
geometry during cleavage, all type II topoisomerases may be able to maintain 
lower levels of cleavage complexes with positively supercoiled DNA. This latter 
characteristic lessens the probability of collisions between DNA tracking systems 
and covalent topoisomerase II-cleaved DNA complexes, thereby decreasing the 
chance that the enzyme will introduce permanent strand breaks into the genome 
during its normal physiological activities. 
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CHAPTER VI 
 
CONCLUSIONS 
 
 DNA in all species ranging from bacteria to humans is globally negatively 
supercoiled (3-6). However, DNA ahead of tracking systems, such as replication 
or transcription complexes, is positively supercoiled (3,5-7). Since topoisomerase 
I can relax positive or negative supercoils (14,19,195), it has been assumed to act 
primarily ahead of DNA tracking systems to alleviate torsional stress. 
Conversely, because topoisomerase II can untangle duplex DNA molecules 
(12,14-16,30), it is assumed to act primarily behind DNA tracking systems to 
resolve knots and links in the DNA. In marked contrast to this proposed 
segregation of function, models for anticancer drug action always place 
topoisomerase II ahead of approaching DNA tracking enzymes, such as the 
replication machinery (15,16,90,196-198). This discrepancy raises the question of 
whether eukaryotic type II topoisomerases have normal physiological functions 
ahead of DNA tracking systems and was the starting point for this dissertation. 
 
Overall Conclusions    
 A number of conclusions can be drawn from the results presented in this 
dissertation. First, human topoisomerase IIα, which is involved in replicative 
processes, displays preferential relaxation of positively supercoiled DNA, the 
substrate generated ahead of DNA tracking complexes such as the replication 
machinery. This suggests that topoisomerase IIα can function efficiently ahead of 
DNA tracking enzymes to alleviate accumulating torsional stress. Topoisomerase 
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IIβ, which is not thought to be involved in DNA replication, does not 
preferentially relax positively supercoiled substrates. These results demonstrate a 
major enzymological difference between the two human isoforms of 
topoisomerase II and is consistent their proposed functions in the cell.
 Second, both topoisomerase IIα and β maintain lower levels of DNA 
cleavage complexes with positively supercoiled substrates. This decreases the 
probability that a collision with DNA tracking enzymes would result in the 
formation of a topoisomerase II-associated double-stranded break in the genetic 
material, suggesting that the human type II enzymes can function safely, under 
normal physiological conditions, ahead of DNA tracking systems.  
 Lower levels of DNA cleavage are also observed in the presence of non-
intercalative topoisomerase II-targeting drugs. However, in the presence of 
intercalative compounds, higher levels of DNA cleavage complexes were 
maintained with positively supercoiled substrates at increasing concentrations of 
drug. These results suggest that intercalative drugs are better suited to target 
topoisomerases on positive supercoils generated ahead of DNA tracking 
complexes, because they do not accumulate in these substrates (as they 
accumulate in negatively supercoiled molecules) and inhibit enzyme activity. 
 Additionally, topoisomerase I maintains higher levels of cleavage complexes 
with positively supercoiled DNA. Thus, this enzyme may be an intrinsically 
more lethal target for anticancer drugs than either topoisomerase IIα or β. 
 Finally, topoisomerase IIα and β distinguish supercoil geometry differently 
during DNA relaxation and cleavage assays. This suggests that the human type 
II enzymes utilize a bimodal mechanism for the recognition of DNA supercoils. 
Taken together, the results observed for the mutant enzymes described in 
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chapter V of this dissertation suggest that while the C-terminal domain appears 
to be necessary for the recognition of supercoil geometry during DNA relaxation, 
the elements of topoisomerase II involved in recognizing supercoil geometry 
during DNA cleavage most likely reside in the conserved N-terminal or central 
domains of the enzyme. 
 
Ramifications 
  The results described in this dissertation lead to interesting proposals not 
only for the normal cellular functions of human topoisomerases, but also for 
these enzymes as important drug targets. While human topoisomerase IIα has 
been believed to work primarily behind DNA tracking systems, such as 
replication complexes, this work demonstrates that this enzyme actually 
preferentially relaxes the substrate generated ahead of replication forks. In 
addition, the ability to maintain lower levels of cleavage complexes with 
positively supercoiled DNA suggests that topoisomerase IIα can work both 
efficiently and safely ahead of DNA tracking systems.  
 Until the publication of the work described in chapter III, human 
topoisomerase IIα and β were thought to be enzymologically similar. However, 
the differential relaxation activities observed with supercoiled substrates 
indicates a major enzymological distinction between the two human isoforms 
and supports the proposed functions of each enzyme in the cell. Additionally, 
the work described in this dissertation demonstrates a catalytic function for the 
variable C-terminal domain of the human type II topoisomerases. Although this 
region is believed to have physiological roles, it was shown to be dispensable for 
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catalysis and previously was thought to play no role in the enzymological 
activities of type II topoisomerases.  
 Finally, the work described in chapter IV of this dissertation demonstrates 
that the supercoil geometry of a DNA substrate can have a profound impact on 
topoisomerase-targeting drugs. It appears that intercalative drugs preferentially 
target topoisomerase II-DNA cleavage complexes formed ahead of DNA tracking 
systems. Additionally, human topoisomerase I seems to be a potentially more 
lethal target than either human type II enzyme, providing a possible reason why 
camptothecin-based drugs are active against cancers that are refractory to other 
established anticancer agents. 
 
Future Directions 
 As described in chapter I of this dissertation, the C-terminal domains of 
DNA gyrase (GyrA) and topoisomerase IV (ParC) adopt a unique fold called a β-
pinwheel (chapter I, Figure 5, left panel) (62-64). The outer rim of this fold was 
observed to be positively charged (chapter I, Figure 5, right panel) and is thought 
to both bind and bend DNA substrates. Computational studies were attempted 
with human topoisomerase IIα to determine whether the human isoform also 
forms a distinct structure for interacting with DNA substrates. Unfortunately, 
homology between the C-terminal domains of the different species of 
topoisomerase II was too low to generate a confident predicted structure. 
However, amino acid sequence alignments comparing the C-terminal domains of 
the bacterial type II topoisomerases and human topoisomerase IIα did reveal 
some promising similarities. The clusters of positively charged residues located 
in the C-terminal region of DNA gyrase and topoisomerase IV and that are 
 119 
responsible for protein-DNA interactions also are found in the C-terminal 
domain of the human type II enzymes. This provides a strong indication that this 
region of topoisomerase IIα may be involved in interacting with the DNA 
substrate.  
 Studies currently are underway to narrow down the region(s) of the C-
terminal domain of topoisomerase IIα responsible for the recognition and 
preferential relaxation of positively supercoiled DNA. This work will include 
additional C-terminal domain truncation mutants of topoisomerase IIα, as well 
as mutations in certain positively charged regions of the C-terminal domain. In 
addition, isolation and purification of the C-terminal domain of topoisomerase 
IIα currently is underway to determine whether this portion of the enzyme can 
independently bind a DNA substrate. Ultimately, these studies could potentially 
lead to a crystal structure of this domain. 
 In an attempt to carry the in vitro results described in this dissertation into a 
cellular setting, it will be of interest to examine the human topoisomerase IIα and 
β C-terminal tail-switched mutants in a mammalian cell system. Human 
topoisomerase IIα and β display different patterns of cellular localization 
throughout the cell cycle, and the C-terminal domains of these enzymes are the 
locations for both nuclear localization sequences and phosphorylation sites. It 
will be interesting to determine whether switching the C-terminal domains of 
human topoisomerase IIα and β has any impact on the localization of either 
enzyme during DNA replication and mitosis, and possibly on any protein-
protein interactions involving these enzymes. It is quite possible that the 
recognition of DNA supercoil geometry observed in vitro will correlate with the 
different functional roles of human topoisomerase IIα and β in cells. 
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 Studies also are underway to more fully assess the interactions between 
positively supercoiled DNA, intercalative drugs, and topoisomerase IIα. Figures 
displayed in this dissertation (see gels in Figures 12, 17, 20, 25 and 27) suggest 
that intercalative compounds, such as ethidium bromide, bind positively 
supercoiled DNA more poorly than negatively supercoiled molecules. We 
proposed in chapter IV that intercalative drugs, such as amsacrine and TAS-103, 
induce higher levels of topoisomerase II-mediated DNA cleavage with positively 
supercoiled substrates at increasing drug concentrations (Figure 24), because 
they do not accumulate on the DNA substrate. To address this hypothesis, we 
currently are designing quantitative binding studies to more fully examine the 
interactions between intercalative topoisomerase II-targeting compounds and 
positively supercoiled substrates.  
 Lastly, in light of the unexpected DNA cleavage results obtained with 
human topoisomerase I on positively supercoiled DNA, studies currently are 
underway to more thoroughly examine the interactions between this human 
enzyme and supercoiled DNA substrates. As discussed in chapter IV, human 
topoisomerase I (unlike the type II enzymes) maintained higher levels of 
cleavage complexes with positively supercoiled substrates. Due to the fact that 
topoisomerase I characteristically functions to alleviate positive supercoiling 
ahead of DNA tracking systems, the cellular ramifications of this enzyme feature 
are unclear. Therefore, it is of interest to our lab to examine how positively 
supercoiled DNA affects the enzymatic activity of human topoisomerase I, how 
this substrate affects the response of the enzyme to different anticancer agents, 
and what elements of topoisomerase I are responsible for discerning DNA 
supercoil geometry. 
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